<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T06:40:49Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4286171" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4286171</identifier>
        <datestamp>2015-10-31</datestamp>
        <setSpec>acssd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" xml:lang="EN">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Proteome Res</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Proteome Res</journal-id>
              <journal-id journal-id-type="publisher-id">pr</journal-id>
              <journal-id journal-id-type="coden">jprobs</journal-id>
              <journal-title-group>
                <journal-title>Journal of Proteome Research</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1535-3893</issn>
              <issn pub-type="epub">1535-3907</issn>
              <publisher>
                <publisher-name>American Chemical
Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4286171</article-id>
              <article-id pub-id-type="pmcid">PMC4286171</article-id>
              <article-id pub-id-type="pmc-uid">4286171</article-id>
              <article-id pub-id-type="pmid">25361234</article-id>
              <article-id pub-id-type="doi">10.1021/pr500782g</article-id>
              <article-categories>
                <subj-group>
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>LC–MS Metabolomics
of Psoriasis Patients Reveals
Disease Severity-Dependent Increases in Circulating Amino Acids That
Are Ameliorated by Anti-TNFα Treatment</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="ath1">
                  <name>
                    <surname>Kamleh</surname>
                    <given-names>Muhammad
Anas</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">†</xref>
                  <xref rid="notes-1" ref-type="notes">⊥</xref>
                </contrib>
                <contrib contrib-type="author" id="ath2">
                  <name>
                    <surname>Snowden</surname>
                    <given-names>Stuart G.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">†</xref>
                  <xref rid="notes-1" ref-type="notes">⊥</xref>
                </contrib>
                <contrib contrib-type="author" id="ath3">
                  <name>
                    <surname>Grapov</surname>
                    <given-names>Dmitry</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">‡</xref>
                </contrib>
                <contrib contrib-type="author" id="ath4">
                  <name>
                    <surname>Blackburn</surname>
                    <given-names>Gavin J.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">§</xref>
                </contrib>
                <contrib contrib-type="author" id="ath5">
                  <name>
                    <surname>Watson</surname>
                    <given-names>David G.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">§</xref>
                </contrib>
                <contrib contrib-type="author" id="ath6">
                  <name>
                    <surname>Xu</surname>
                    <given-names>Ning</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">∥</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes" id="ath7">
                  <name>
                    <surname>Ståhle</surname>
                    <given-names>Mona</given-names>
                  </name>
                  <xref rid="cor1" ref-type="other">*</xref>
                  <xref rid="aff4" ref-type="aff">∥</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes" id="ath8">
                  <name>
                    <surname>Wheelock</surname>
                    <given-names>Craig E.</given-names>
                  </name>
                  <xref rid="cor2" ref-type="other">*</xref>
                  <xref rid="aff1" ref-type="aff">†</xref>
                </contrib>
                <aff id="aff1"><label>†</label>Department
of Medical Biochemistry and Biophysics, Division of Physiological
Chemistry 2, <institution>Karolinska Institutet</institution>, SE-17177 Stockholm, <country>Sweden</country></aff>
                <aff id="aff2"><label>‡</label>NIH
West Coast Metabolomics Center, <institution>University
of California</institution>, Davis, California 95616, <country>United States</country></aff>
                <aff id="aff3"><label>§</label><institution>Strathclyde
Institute of Pharmacy and Biomedical Science</institution>, 161 Cathedral Street, Glasgow G4 0RE, <country>United Kingdom</country></aff>
                <aff id="aff4"><label>∥</label>Dermatology
Unit, Department of Medicine, <institution>Karolinska
Institutet</institution>, SE-17176 Stockholm, <country>Sweden</country></aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>*</label>(M.S.)
Phone: <phone>+46 08-517
733 48</phone>. E-mail: <email>mona.stahle@ki.se</email>.</corresp>
                <corresp id="cor2"><label>*</label>(C.E.W.) Phone: <phone>+46 08-524
876 30</phone>. Fax: <fax>+46 (0)8 736-0439</fax>. E-mail: <email>craig.wheelock@ki.se</email>.</corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>31</day>
                <month>10</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>31</day>
                <month>10</month>
                <year>2014</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>02</day>
                <month>01</month>
                <year>2015</year>
              </pub-date>
              <volume>14</volume>
              <issue>1</issue>
              <issue-title>Environmental Impact on Health</issue-title>
              <fpage>557</fpage>
              <lpage>566</lpage>
              <history>
                <date date-type="received">
                  <day>02</day>
                  <month>08</month>
                  <year>2014</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2014 American
Chemical Society</copyright-statement>
                <copyright-year>2014</copyright-year>
                <copyright-holder>American
Chemical Society</copyright-holder>
                <license>
                  <license-p>This is an open access article published under an ACS AuthorChoice <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.</license-p>
                </license>
              </permissions>
              <abstract>
                <p content-type="toc-graphic">
                  <graphic xlink:href="pr-2014-00782g_0004" id="ab-d31e218"/>
                </p>
                <p>Psoriasis is an immune-mediated highly
heterogeneous skin disease
in which genetic as well as environmental factors play important roles.
In spite of the local manifestations of the disease, psoriasis may
progress to affect organs deeper than the skin. These effects are
documented by epidemiological studies, but they are not yet mechanistically
understood. In order to provide insight into the systemic effects
of psoriasis, we performed a nontargeted high-resolution LC–MS
metabolomics analysis to measure plasma metabolites from individuals
with mild or severe psoriasis as well as healthy controls. Additionally,
the effects of the anti-TNFα drug Etanercept on metabolic profiles
were investigated in patients with severe psoriasis. Our analyses
identified significant psoriasis-associated perturbations in three
metabolic pathways: (1) arginine and proline, (2) glycine, serine
and threonine, and (3) alanine, aspartate, and glutamate. Etanercept
treatment reversed the majority of psoriasis-associated trends in
circulating metabolites, shifting the metabolic phenotypes of severe
psoriasis toward that of healthy controls. Circulating metabolite
levels pre- and post-Etanercept treatment correlated with psoriasis
area and severity index (PASI) clinical scoring (<italic>R</italic><sup>2</sup> = 0.80; <italic>p</italic> &lt; 0.0001). Although the
responsible mechanism(s) are unclear, these results suggest that psoriasis
severity-associated metabolic perturbations may stem from increased
demand for collagen synthesis and keratinocyte hyperproliferation
or potentially the incidence of cachexia. Data suggest that levels
of circulating amino acids are useful for monitoring both the severity
of disease as well as therapeutic response to anti-TNFα treatment.</p>
              </abstract>
              <kwd-group>
                <kwd>Mass spectrometry</kwd>
                <kwd>metabolomics</kwd>
                <kwd>psoriasis</kwd>
                <kwd>pathway enrichment</kwd>
                <kwd>HILIC</kwd>
                <kwd>keratinocyte</kwd>
                <kwd>collagen</kwd>
                <kwd>Etanercept</kwd>
                <kwd>diabetes</kwd>
              </kwd-group>
              <funding-group>
                <funding-statement>
                  <funding-source>National Institutes of Health, United States</funding-source>
                </funding-statement>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>document-id-old-9</meta-name>
                  <meta-value>pr500782g</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>document-id-new-14</meta-name>
                  <meta-value>pr-2014-00782g</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>ccc-price</meta-name>
                  <meta-value/>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1">
              <title>Introduction</title>
              <p>Psoriasis is an immune-mediated
skin disease associated with significant
morbidity and mortality.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> The ultimate
cause of psoriasis remains unclear, but it involves triggering the
immune system, leading to sustained inflammation and dysregulation
of keratinocyte differentiation.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Psoriasis
is a heterogeneous disease with significant comorbidities including,
in particular, psoriatic arthritis.<sup><xref ref-type="bibr" rid="ref3">3</xref>−<xref ref-type="bibr" rid="ref5">5</xref></sup> Genome-wide association
studies indicate a large genetic component in the pathogenesis of
psoriasis.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> In particular, the HLA-C gene
is estimated to contribute ∼50% to the heritability in early
onset psoriasis.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Once activated, dendritic
cells stimulate differentiation and migration of Th1 and Th17 effector
T cells to the skin, which, through cytokine release, immune cell
recruitment, and keratinocyte proliferation, drive a sustained cycle
of chronic inflammation.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Patients with
psoriasis are also at a significant risk of developing metabolic syndrome,
type 2 diabetes, hypertension, and obesity.<sup><xref ref-type="bibr" rid="ref9">9</xref>−<xref ref-type="bibr" rid="ref11">11</xref></sup> The underlying
mechanisms are still unclear, and, to date, comorbidities are supported
primarily by epidemiological data.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup></p>
              <p>The cytokine tumor necrosis factor alpha (TNFα) is known
to play a major role in the pathophysiology of psoriasis,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> and anti-TNFα therapeutics are routinely
used to treat immune-mediated diseases including psoriasis as well
as psoriatic and rheumatoid arthritis in adult as well as pediatric
populations.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> One of the first-line anti-TNFα
treatments is the biologic Etanercept, which has demonstrated efficacy
in resolving psoriatic lesions. Etanercept is a fusion protein that
binds to the constant end of the IgG1 antibody<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> and
acts as a competitive inhibitor of TNFα. Although it significantly
suppresses the associated inflammation, Etanercept, as well as other
biologic therapeutics, does not cure the underlying disease.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> TNFα is also involved in other physiological
processes such as muscle protein proteolysis and cachexia,<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> thereby suggesting additional pathways by which
anti-TNFα therapeutics may affect the underlying pathophysiology
of the disease.</p>
              <p>In order to investigate the systemic biochemical
shifts associated
with disease severity, liquid chromatography high-resolution mass
spectrometry (LC–HRMS) metabolomic analysis was used to characterize
circulating metabolites in psoriasis patients. Metabolomics profiles
were also compared before and after a 12 week treatment with Etanercept.
A metabolomics-based research approach involves simultaneously analyzing
the complement of small molecules (metabolites) in a system. This
has been shown to be useful for identifying metabolic traits that
represent intermediate phenotypes capable of linking genetic and environmental
factors to heterogeneous diseases.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref19">19</xref></sup> This study
is, to the best of our knowledge, the first to examine the metabolic
profile associated with plaque psoriasis severity and the effects
of Etanercept treatment. These results provide insight into the biochemical
pathways involved in the etiology of psoriasis and the systemic effects
of Etanercept treatment.</p>
            </sec>
            <sec id="sec2">
              <title>Experemintal Section</title>
              <sec id="sec2.1">
                <title>Study Design</title>
                <p>Healthy
controls as well as patients with
mild or severe psoriasis were recruited at the Karolinska University
Hospital. Mild psoriasis patients were recruited from a cohort of
patients with newly onset psoriasis who did not require systemic therapy
and were therefore treated only topically. Severe psoriasis patients
required systemic therapy to control the skin manifestations of the
disease. None of the patients were on statins or prescribed anti-inflammatory
drugs. All samples were obtained prior to the commencement of any
treatment. The recruitment group consisted of 96 gender-balanced individuals
(32 healthy controls and 32 mild and 32 severe psoriasis). For analysis
purposes, the full cohort (<italic>n</italic> = 96) was subdivided
into two gender- and disease severity-balanced groups (<italic>n</italic> = 48 each), called exploratory and validation cohorts (Table <xref rid="tbl1" ref-type="other">1</xref>). The exploratory cohort was used to identify metabolic
markers for psoriasis severity, and the validation cohort as a confirmation
of the identified trends. Additional plasma samples were taken from
the severe psoriasis patients (<italic>n</italic> = 16) in the validation
cohort following 12 weeks of Etanercept (Enbrel) treatment (50 mg
once per week subcutaneously), and this group is referred to as the
treatment cohort. For blood collection, 10 mL of whole blood was collected
in EDTA tubes after overnight fasting. Samples were left standing
for 1 h before centrifugation at room temperature for 20 min at 3100
rpm. After centrifugation, samples were aliquoted and immediately
stored at −70 °C until use. Psoriasis disease was judged
as severe when it required systemic therapy and was evaluated by the
psoriasis area and severity index (PASI), which is an established
measurement that quantifies the thickness, redness, scaling, and distribution
of psoriasis lesions.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> The study was approved
by the Regional Committee of Ethics and was performed according to
the Declaration of Helsinki Principles. Signed consent forms were
collected from all sample donors.</p>
              </sec>
              <sec id="sec2.2">
                <title>HILIC Mode Metabolomics</title>
                <p>A cocktail of four internal
standards (10 μL; <xref rid="notes-2" ref-type="notes">Table S1</xref>) was added
to 50 μL of EDTA plasma. Proteins were precipitated using 200
μL of HPLC grade acetonitrile (Rathburn). Samples were vortexed
for 5 s and then left to stand on ice for 10 min followed by centrifugation
at 15 000 rcf for 10 min at 4 °C. The supernatant (150
μL) was transferred to a clean Eppendorf tube, and 20 μL
of each sample was used to produce a pooled quality control. Samples
were stored at −20 °C prior to analysis. Prepared samples
were analyzed on a Thermo Ultimate 3000 HPLC and Thermo Q-Exactive
(Orbitrap) mass spectrometer. Ten microliters of sample was injected
on a Merck Sequant ZIC-HILIC column (150 × 4.6 mm, 5 μm
particle size) coupled to a Merck Sequant ZIC-HILIC guard column (20
× 2.1 mm). Mass spectrometry data were acquired (full scan mode)
in both positive and negative ionization modes, using 140 000
mass resolution.</p>
              </sec>
              <sec id="sec2.3">
                <title>Reversed-Phase (RP) Metabolomics</title>
                <p>A cocktail of five
internal standards (10 μL; <xref rid="notes-2" ref-type="notes">Table S1</xref>) was added to 50 μL of EDTA plasma followed by 150 μL
of chilled (−20 °C) methanol (Rathburn) for protein precipitation.
Samples were vortexed for 5 s and left to stand for 2 h at −20
°C, followed by centrifugation at 15 000 rcf for 12 min
at 4 °C. The supernatant (90 μL) was transferred to a clean
Eppendorf tube, and 10 μL of each sample was used to produce
a pooled quality control. On the analysis day, samples were diluted
1:1 with Milli-Q water (Millipore). Prepared samples were analyzed
on a Thermo Ultimate 3000 HPLC and Thermo Q-Exactive (Orbitrap) mass
spectrometer. Twenty microliters of sample was injected on a Thermo
Accucore aQ RP C18 column (150 × 2.1 mm, 2.7 μm particle
size). Mass spectrometry data were acquired (full scan mode) in both
positive and negative ionization modes, using 70 000 mass resolution.
Detailed methods are provided in the <xref rid="notes-2" ref-type="notes">Supporting
Information</xref>.</p>
              </sec>
              <sec id="sec2.4">
                <title>Data Processing and Metabolite Annotation</title>
                <p>RAW files
were converted to universal mzXML file using MSconvert.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> All chromatograms were evaluated using the open
source software package XCMS<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> performed
in R.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> For the preliminary analysis, metabolites
were annotated by matching accurate mass and retention time (AMRT)
to authentic chemical reference standards. Variables of importance
identified from the multivariate analyses (see <xref rid="sec2.5" ref-type="other">Statistical Analysis</xref>) were subjected to further identity confirmation
by comparing fragmentation patterns to those of chemical standards.
The MS/MS spectra of all reported metabolites matched those of the
standards with the exception of inosine (which was excluded from further
analysis). Data analysis was limited to metabolites matching the AMRT
and MS/MS fragmentation spectra of standards except for sphingosine-1-phosphate
and GlcCer(C16:0), which were identified only by AMRT. The coefficient
of variance (CV) of the HILIC internal standard cocktail was &lt;35%,
and for reversed-phase, &lt;15%. All CVs of the discussed metabolites
were &lt;30%, except for cystathionine and cytidine (exploratory and
validation cohorts) and cysteine and proline (validation cohort only).
The median CV for the identified metabolites was 14.8 and 16.0% for
the exploratory and validation cohorts, respectively.</p>
              </sec>
              <sec id="sec2.5">
                <title>Statistical
Analysis</title>
                <p>Statistical analysis was used
to identify significantly altered metabolites within the exploratory
and validation cohorts between (1) control and mild, (2) control and
severe, (3) mild and severe, and (4) severe pre- and post-treatment
with Etanercept (validation cohort only) psoriasis patients. Comparisons
for 1–3 were made using two-sample <italic>t</italic>-tests,
and for 4, based on a paired <italic>t</italic>-test carried out in
the R statistical programming environment.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> The false discovery rate (FDR) due to the multiple hypotheses tested
was adjusted according to Benjamini and Hochberg (<italic>q</italic> = 0.05)<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> and reported as <italic>p</italic><sub>adj</sub>. FDR was also directly estimated according to Dabney
and Storey<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> and reported as the <italic>q</italic>-value.</p>
                <p>Multivariate analysis was performed using
a combination of principal component analysis (PCA) and orthogonal
projection to latent structures–discriminant analysis (OPLS-DA)
using SIMCA-P 13 (Umetrics, Umeå, Sweden). OPLS-DA was conducted
following logarithmic transformation (base 10), mean centering, and
scaling to unit variance (UV). OPLS-DA model performance was evaluated
based on the cumulative coefficient of correlation between group labels
(<italic>Y</italic>) and model projection of metabolites (<italic>X</italic>) (<italic>R</italic><sup>2</sup><italic>Y</italic><sub>cum</sub>) and 7-fold cross-validated model fit to the data (<italic>Q</italic><sup>2</sup><sub>cum</sub>), the significance of which
was assessed through cross-validation analysis of variance (CV-ANOVA).
Model predictive and orthogonal components are reported as (predictive
+ orthogonal). Iterative feature selection (2 rounds) was performed
to identify important metabolic discriminants between the compared
populations. Metabolites were retained in the model based on a combination
of variable importance in projection (VIP) &gt; 1.0 and absolute magnitude
of correlation with model scores (<italic>p</italic><sub>corr</sub> &gt; 0.4).<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> SIMCA-P was used to calculate
the PLS inner relation between disease severity score (PASI) and correlated
metabolites (|Pearson’s correlations| &gt; 0.5).</p>
              </sec>
              <sec id="sec2.6">
                <title>Pathway Enrichment
Analysis</title>
                <p>Biochemical pathway enrichment
analysis was used to identify psoriasis-dependent changes in global
biochemical domains. MetaboAnalyst<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> was
used to test for significant enrichment in KEGG pathways (<uri xlink:href="http://www.genome.jp/kegg/">http://www.genome.jp/kegg/</uri>) among the noted metabolic perturbations in common to both the exploratory
and validation cohorts (Table <xref rid="tbl2" ref-type="other">2</xref>). Significant
enrichment was assessed on the basis of the false discovery rate-adjusted
hypergeometric test statistic (<italic>p</italic> ≤ 0.05),
and impact on pathway topology was defined based on relative-betweeness
centrality.</p>
              </sec>
              <sec id="sec2.7">
                <title>Partial Correlation Network Analysis</title>
                <p>Gaussian graphical
model networks were calculated for metabolite relationships in the
context of the identified differences between (1) control and severe,
(2) control and treated severe, and (3) untreated and treated severe
psoriasis patients from the validation cohort. <italic>q</italic>-order
partial correlations (<italic>q</italic> = 1, 12, 24, 35)<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> were calculated (<italic>n</italic> = 1000)
in R (v3.0.1)<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> between metabolites (<italic>n</italic> = 93) from the validation data set, excluding patients
with mild psoriasis (<italic>n</italic> = 48). To maximize network
node inclusion and minimize edge degree, a threshold of β =
0.4 for the average nonrejection rate (β) for metabolite pairwise
relationships was selected. Using this approach, a smaller average
nonrejection rate corresponds to stronger <italic>q</italic>-order
partial correlation. Spearman’s rank order coefficients of
correlation, <italic>p</italic>-values, and FDR-adjusted <italic>p</italic>-values (<italic>p</italic><sub>adj</sub>)<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> were calculated for all <italic>q</italic>-order selected relationships.
Cytoscape<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> was used to generate network
visualizations for all edges displaying <italic>p</italic><sub>adj</sub> ≤ 0.05 (83 edges or 90% of the original <italic>q</italic>-order calculated edges). Network mapping was used to encode and
display statistical and multivariate analysis results within the context
of the partial correlation defined relationships.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec3">
              <title>Results</title>
              <p>Psoriasis patients and control characteristics were consistent
between the exploratory and validation cohorts (Table <xref rid="tbl1" ref-type="other">1</xref>). PASI scoring significantly
increased (<italic>p</italic> &lt; 0.05) with disease severity in
both cohorts and decreased following Etanercept treatment (Table <xref rid="tbl1" ref-type="other">1</xref>). HILIC mode and reversed-phase metabolomic analyses
of the exploratory and validation cohorts’ plasma were used
to identify 94 and 93 metabolites from the XCMS diffreport of all
samples, respectively (67 of which were in common), through matching
of retention time and spectra to external standards (<xref rid="notes-2" ref-type="notes">Table S2</xref>). Statistical analyses of the metabolomic measurements
with adjustment for FDR were used to identify significantly altered
compounds among control, mild, and severe psoriasis patients for both
the exploratory and validation cohorts (<xref rid="notes-2" ref-type="notes">Tables
S3 and S4</xref>) and between severe and severe Etanercept-treated
psoriasis patients in the validation cohort (<xref rid="notes-2" ref-type="notes">Table
S4</xref>). Additionally, changes in &gt;150 metabolite features putatively
identified based on only accurate mass are reported for the comparisons
between severe psoriasis patients and controls in both cohorts (<xref rid="notes-2" ref-type="notes">Tables S5 and S6</xref>) and between severe psoriasis
patients at baseline and after Etanercept treatment (<xref rid="notes-2" ref-type="notes">Table S7</xref>).</p>
              <table-wrap id="tbl1" position="float">
                <label>Table 1</label>
                <caption>
                  <title>Characteristics of the Study Cohorts<xref rid="t1fn1" ref-type="table-fn">a</xref></title>
                </caption>
                <table frame="hsides" rules="groups" border="0">
                  <colgroup>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th style="border:none;" align="center"> </th>
                      <th colspan="3" align="center">exploratory cohort<hr/></th>
                    </tr>
                    <tr>
                      <th style="border:none;" align="center"> </th>
                      <th style="border:none;" align="center">control</th>
                      <th style="border:none;" align="center">mild</th>
                      <th style="border:none;" align="center">severe</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td style="border:none;" align="left">gender</td>
                      <td style="border:none;" align="left">8/8<xref rid="t1fn4" ref-type="table-fn">d</xref></td>
                      <td style="border:none;" align="left">8/8</td>
                      <td style="border:none;" align="left">8/8</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">age (years)</td>
                      <td style="border:none;" align="left">52 ± 9</td>
                      <td style="border:none;" align="left">52 ± 8</td>
                      <td style="border:none;" align="left">58 ± 10</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">BMI<xref rid="t1fn2" ref-type="table-fn">b</xref></td>
                      <td style="border:none;" align="left">26.1 ± 4.1</td>
                      <td style="border:none;" align="left">25.0 ± 4.8</td>
                      <td style="border:none;" align="left">28.4 ± 3.5</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">PASI<xref rid="t1fn3" ref-type="table-fn">c</xref></td>
                      <td style="border:none;" align="left">n/a</td>
                      <td style="border:none;" align="left">1.4 ± 0.7<xref rid="t1fn5" ref-type="table-fn">e</xref></td>
                      <td style="border:none;" align="left">16.5 ± 7.4<xref rid="t1fn5" ref-type="table-fn">e</xref></td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">cholesterol</td>
                      <td style="border:none;" align="left">5.2 ± 0.8</td>
                      <td style="border:none;" align="left">5.1 ± 0.9</td>
                      <td style="border:none;" align="left">4.8 ± 0.9</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">triglycerides</td>
                      <td style="border:none;" align="left">1.0 ± 0.4</td>
                      <td style="border:none;" align="left">1.0 ± 0.56</td>
                      <td style="border:none;" align="left">1.3 ± 0.5</td>
                    </tr>
                  </tbody>
                </table>
                <table frame="hsides" rules="groups" border="0">
                  <colgroup>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th style="border:none;" align="center"> </th>
                      <th colspan="4" align="center">validation
cohort<hr/></th>
                    </tr>
                    <tr>
                      <th style="border:none;" align="center"> </th>
                      <th style="border:none;" align="center">control</th>
                      <th style="border:none;" align="center">mild</th>
                      <th style="border:none;" align="center">severe</th>
                      <th style="border:none;" align="center">severe (treated)<xref rid="t1fn6" ref-type="table-fn">f</xref></th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td style="border:none;" align="left">gender</td>
                      <td style="border:none;" align="left">8/8</td>
                      <td style="border:none;" align="left">8/8</td>
                      <td style="border:none;" align="left">8/8</td>
                      <td style="border:none;" align="left">8/8</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">age (years)</td>
                      <td style="border:none;" align="left">44 ± 13</td>
                      <td style="border:none;" align="left">42 ± 20</td>
                      <td style="border:none;" align="left">53 ± 13</td>
                      <td style="border:none;" align="left">53 ± 13</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">BMI</td>
                      <td style="border:none;" align="left">24.0 ± 3.1</td>
                      <td style="border:none;" align="left">25.2 ± 4.7</td>
                      <td style="border:none;" align="left">27.3 ± 4.8</td>
                      <td style="border:none;" align="left">27.2 ± 4.6</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">waistline (cm)</td>
                      <td style="border:none;" align="left">n/d</td>
                      <td style="border:none;" align="left">n/d</td>
                      <td style="border:none;" align="left">98 ± 13.8</td>
                      <td style="border:none;" align="left">97 ± 12.9</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">PASI</td>
                      <td style="border:none;" align="left">n/a</td>
                      <td style="border:none;" align="left">1.6 ± 1.0<xref rid="t1fn5" ref-type="table-fn">e</xref></td>
                      <td style="border:none;" align="left">13.6 ± 4.5<xref rid="t1fn5" ref-type="table-fn">e</xref></td>
                      <td style="border:none;" align="left">4.9 ± 3.4<xref rid="t1fn7" ref-type="table-fn">g</xref></td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">cholesterol</td>
                      <td style="border:none;" align="left">5.1 ± 0.8</td>
                      <td style="border:none;" align="left">4.9 ± 0.9</td>
                      <td style="border:none;" align="left">5.3 ± 0.6</td>
                      <td style="border:none;" align="left">6.57 ± 4.1<xref rid="t1fn8" ref-type="table-fn">h</xref></td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">triglycerides</td>
                      <td style="border:none;" align="left">1.1 ± 0.6</td>
                      <td style="border:none;" align="left">1.2 ± 1.0</td>
                      <td style="border:none;" align="left">1.0 ± 0.4</td>
                      <td style="border:none;" align="left">1.7 ± 0.9</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="t1fn1">
                    <label>a</label>
                    <p>Values are reported
as the mean
± SD. Units for cholesterol and triglycerides are mmol/L. n/d
indicates that the value was not determined.</p>
                  </fn>
                  <fn id="t1fn2">
                    <label>b</label>
                    <p>BMI, body mass index.</p>
                  </fn>
                  <fn id="t1fn3">
                    <label>c</label>
                    <p>PASI, psoriasis area and severity
index. There is no PASI score for the control group (n/a).</p>
                  </fn>
                  <fn id="t1fn4">
                    <label>d</label>
                    <p>Gender balance: male/female.</p>
                  </fn>
                  <fn id="t1fn5">
                    <label>e</label>
                    <p><italic>p</italic>-value &lt; 0.05
for a two-sample <italic>t</italic>-test for the PASI score between
mild and severe psoriasis subjects.</p>
                  </fn>
                  <fn id="t1fn6">
                    <label>f</label>
                    <p>Severe psoriasis patients treated
with Etanercept for 12 weeks.</p>
                  </fn>
                  <fn id="t1fn7">
                    <label>g</label>
                    <p><italic>p</italic>-value &lt; 0.05
for a paired two-sample <italic>t</italic>-test for the PASI score
for treated vs untreated severe psoriasis.</p>
                  </fn>
                  <fn id="t1fn8">
                    <label>h</label>
                    <p><italic>p</italic>-value &lt; 0.05
based on a paired <italic>t</italic>-test.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>As expected, the largest effect size was observed
between control
and severe psoriasis patients, with 33 and 34 significantly (<italic>p</italic><sub>adj</sub> ≤ 0.05) perturbed plasma metabolites
in the exploratory and validation cohorts, respectively (<xref rid="notes-2" ref-type="notes">Tables S3 and S4</xref>). Comparison of the psoriasis-associated
metabolic alterations in common to both cohorts identified 20 significantly
(<italic>p</italic><sub>adj</sub> ≤ 0.05) altered metabolites,
17 of which increased with psoriasis severity in both cohorts (Table <xref rid="tbl2" ref-type="other">2</xref>). In particular, ornithine
and another urea cycle intermediate, citrulline, increased by 215
and 90%, on average, respectively, in severe psoriasis patients compared
to that in controls (Table <xref rid="tbl2" ref-type="other">2</xref>). Etanercept treatment
led to reductions in 10 of the 20 (50%) previously identified psoriasis-associated
metabolic dysregulations (Table <xref rid="tbl2" ref-type="other">2</xref>). Specifically,
treatment resulted in significant reductions in amino acids, highlighted
by 230, 233, and 150% decreases in threonine, ornithine, and methionine,
respectively (Table <xref rid="tbl2" ref-type="other">2</xref>). Comparison of Etanercept-treated
severe psoriasis to controls revealed a normalization in the majority
(89%) of metabolites previously shown to be increased with disease.
Although cystine was significantly reduced by 10% following treatment,
this amino acid remained 60% elevated in the treated group relative
to that in controls (Table <xref rid="tbl2" ref-type="other">2</xref>). Cystathionine
was the only metabolite in common to both cohorts that was reduced
(80%) in severe psoriasis compared to that in controls and was not
significantly affected by Etanercept treatment (Table <xref rid="tbl2" ref-type="other">2</xref>). Similarly, sphingosine-1-phosphate levels were not affected
by treatment and remained 70% elevated in the treated group (Table <xref rid="tbl2" ref-type="other">2</xref>).</p>
              <table-wrap id="tbl2" position="float">
                <label>Table 2</label>
                <caption>
                  <title>Fold Changes in Metabolites
Associated
with Severe Psoriasis That Showed Similar Patterns in the Exploratory
and Validation Cohorts</title>
                </caption>
                <table frame="hsides" rules="groups" border="0">
                  <colgroup>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th style="border:none;" align="center"> </th>
                      <th style="border:none;" align="center"> </th>
                      <th colspan="2" align="center">exploratory cohort<hr/></th>
                      <th colspan="2" align="center">validation cohort<hr/></th>
                      <th colspan="4" align="center">Etanercept treated cohort<hr/></th>
                    </tr>
                    <tr>
                      <th style="border:none;" align="center"> </th>
                      <th style="border:none;" align="center"> </th>
                      <th colspan="2" align="center">severe
vs control<xref rid="t2fn2" ref-type="table-fn">b</xref><hr/></th>
                      <th colspan="2" align="center">severe vs control<hr/></th>
                      <th colspan="2" align="center">treated vs severe<hr/></th>
                      <th colspan="2" align="center">treated vs control<hr/></th>
                    </tr>
                    <tr>
                      <th style="border:none;" align="center">pathway</th>
                      <th style="border:none;" align="center">metabolite<xref rid="t2fn1" ref-type="table-fn">a</xref></th>
                      <th style="border:none;" align="center"><italic>q</italic>-value<xref rid="t2fn3" ref-type="table-fn">c</xref></th>
                      <th style="border:none;" align="center">FC<xref rid="t2fn4" ref-type="table-fn">d</xref></th>
                      <th style="border:none;" align="center"><italic>q</italic>-value</th>
                      <th style="border:none;" align="center">FC</th>
                      <th style="border:none;" align="center"><italic>q</italic>-value</th>
                      <th style="border:none;" align="center">FC</th>
                      <th style="border:none;" align="center"><italic>q</italic>-value</th>
                      <th style="border:none;" align="center">FC</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td rowspan="5" style="border:none;" align="left">arginine and
proline pathway<xref rid="t2fn5" ref-type="table-fn">e</xref></td>
                      <td style="border:none;" align="left">arginine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">1.82 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">2.47</td>
                      <td style="border:none;" align="char" char=".">1.43 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">2.29</td>
                      <td style="border:none;" align="char" char=".">7.58 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">0.45</td>
                      <td style="border:none;" align="char" char=".">7.48 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.02</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">citrulline<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">4.09 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">2.61</td>
                      <td style="border:none;" align="char" char=".">1.16 × 10<sup>–5</sup></td>
                      <td style="border:none;" align="char" char=".">1.88</td>
                      <td style="border:none;" align="char" char=".">1.46 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">0.64</td>
                      <td style="border:none;" align="char" char=".">4.07 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.19</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">ornithine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">6.92 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">3.37</td>
                      <td style="border:none;" align="char" char=".">1.77 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">2.92</td>
                      <td style="border:none;" align="char" char=".">2.18 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">0.41</td>
                      <td style="border:none;" align="char" char=".">4.07 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.21</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">proline<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">1.24 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">1.83</td>
                      <td style="border:none;" align="char" char=".">1.40 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">1.89</td>
                      <td style="border:none;" align="char" char=".">1.09 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.65</td>
                      <td style="border:none;" align="char" char=".">4.16 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.22</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">hydroxyproline<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">2.16 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">2.93</td>
                      <td style="border:none;" align="char" char=".">6.88 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">1.81</td>
                      <td style="border:none;" align="char" char=".">7.87 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">0.69</td>
                      <td style="border:none;" align="char" char=".">3.99 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.25</td>
                    </tr>
                    <tr>
                      <td rowspan="3" style="border:none;" align="left">glycine,
serine,
and threonine pathway<xref rid="t2fn6" ref-type="table-fn">f</xref></td>
                      <td style="border:none;" align="left">glycine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">9.42 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">2.13</td>
                      <td style="border:none;" align="char" char=".">2.87 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">1.68</td>
                      <td style="border:none;" align="char" char=".">2.18 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">0.49</td>
                      <td style="border:none;" align="char" char=".">3.99 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.83</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">serine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">4.74 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">1.96</td>
                      <td style="border:none;" align="char" char=".">1.15 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">1.61</td>
                      <td style="border:none;" align="char" char=".">1.35 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.78</td>
                      <td style="border:none;" align="char" char=".">3.58 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.25</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">threonine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">4.09 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">2.68</td>
                      <td style="border:none;" align="char" char=".">3.99 × 10<sup>–6</sup></td>
                      <td style="border:none;" align="char" char=".">2.58</td>
                      <td style="border:none;" align="char" char=".">7.77 × 10<sup>–7</sup></td>
                      <td style="border:none;" align="char" char=".">0.32</td>
                      <td style="border:none;" align="char" char=".">3.85 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.82</td>
                    </tr>
                    <tr>
                      <td rowspan="3" style="border:none;" align="left">alanine,
aspartate,
and glutamate pathway<xref rid="t2fn7" ref-type="table-fn">g</xref></td>
                      <td style="border:none;" align="left">aspartate<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">7.66 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">2.43</td>
                      <td style="border:none;" align="char" char=".">2.63 × 10<sup>–5</sup></td>
                      <td style="border:none;" align="char" char=".">1.96</td>
                      <td style="border:none;" align="char" char=".">1.39 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.69</td>
                      <td style="border:none;" align="char" char=".">3.99 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.34</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">glutamate<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">1.26 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">3.00</td>
                      <td style="border:none;" align="char" char=".">4.80 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">2.22</td>
                      <td style="border:none;" align="char" char=".">3.33 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.78</td>
                      <td style="border:none;" align="char" char=".">3.58 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.72</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">glutamine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">1.75 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">2.03</td>
                      <td style="border:none;" align="char" char=".">4.26 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">1.71</td>
                      <td style="border:none;" align="char" char=".">7.34 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">0.59</td>
                      <td style="border:none;" align="char" char=".">7.48 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.02</td>
                    </tr>
                    <tr>
                      <td rowspan="3" style="border:none;" align="left">cysteine
and
methionine pathway<xref rid="t2fn8" ref-type="table-fn">h</xref></td>
                      <td style="border:none;" align="left">cystine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">4.07 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">2.81</td>
                      <td style="border:none;" align="char" char=".">1.77 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">1.83</td>
                      <td style="border:none;" align="char" char=".">2.86 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.9</td>
                      <td style="border:none;" align="char" char=".">6.07 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">1.64</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">cystathionine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">1.13 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">0.83</td>
                      <td style="border:none;" align="char" char=".">3.99 × 10<sup>–6</sup></td>
                      <td style="border:none;" align="char" char=".">0.31</td>
                      <td style="border:none;" align="char" char=".">2.96 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.51</td>
                      <td style="border:none;" align="char" char=".">1.94 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">0.47</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">methionine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">1.41 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">2.15</td>
                      <td style="border:none;" align="char" char=".">1.77 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">1.84</td>
                      <td style="border:none;" align="char" char=".">4.82 × 10<sup>–5</sup></td>
                      <td style="border:none;" align="char" char=".">0.42</td>
                      <td style="border:none;" align="char" char=".">3.58 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.78</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">taurine and hypotaurine
pathway<xref rid="t2fn9" ref-type="table-fn">i</xref></td>
                      <td style="border:none;" align="left">taurine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">2.70 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">1.92</td>
                      <td style="border:none;" align="char" char=".">4.96 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">1.47</td>
                      <td style="border:none;" align="char" char=".">1.79 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.82</td>
                      <td style="border:none;" align="char" char=".">3.38 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.21</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">phenylalanine
pathway<xref rid="t2fn10" ref-type="table-fn">j</xref></td>
                      <td style="border:none;" align="left">phenylalanine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">1.90 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">1.34</td>
                      <td style="border:none;" align="char" char=".">1.89 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">1.48</td>
                      <td style="border:none;" align="char" char=".">4.52 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">0.73</td>
                      <td style="border:none;" align="char" char=".">5.38 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.07</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">pyrimidine pathway<xref rid="t2fn11" ref-type="table-fn">k</xref></td>
                      <td style="border:none;" align="left">cytidine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">7.80 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">2.09</td>
                      <td style="border:none;" align="char" char=".">2.55 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">2.47</td>
                      <td style="border:none;" align="char" char=".">2.42 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.65</td>
                      <td style="border:none;" align="char" char=".">3.58 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.6</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">amino sugar pathway<xref rid="t2fn12" ref-type="table-fn">l</xref></td>
                      <td style="border:none;" align="left">acetylglucosamine<xref rid="t2fn14" ref-type="table-fn">o</xref></td>
                      <td style="border:none;" align="center">6.92 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">2.36</td>
                      <td style="border:none;" align="char" char=".">2.90 × 10<sup>–3</sup></td>
                      <td style="border:none;" align="char" char=".">1.34</td>
                      <td style="border:none;" align="char" char=".">7.87 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">0.72</td>
                      <td style="border:none;" align="char" char=".">7.12 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.96</td>
                    </tr>
                    <tr>
                      <td rowspan="2" style="border:none;" align="left">sphingolipid
pathway<xref rid="t2fn13" ref-type="table-fn">m</xref></td>
                      <td style="border:none;" align="left">glucosylceramide (C16:0)<xref rid="t2fn15" ref-type="table-fn">p</xref></td>
                      <td style="border:none;" align="center">4.29 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">1.46</td>
                      <td style="border:none;" align="char" char=".">1.01 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">1.59</td>
                      <td style="border:none;" align="char" char=".">4.34 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.95</td>
                      <td style="border:none;" align="char" char=".">3.02 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">1.51</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">sphingosine-1-phosphate<xref rid="t2fn15" ref-type="table-fn">p</xref></td>
                      <td style="border:none;" align="center">3.54 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">1.21</td>
                      <td style="border:none;" align="char" char=".">1.89 × 10<sup>–4</sup></td>
                      <td style="border:none;" align="char" char=".">1.93</td>
                      <td style="border:none;" align="char" char=".">3.06 × 10<sup>–1</sup></td>
                      <td style="border:none;" align="char" char=".">0.88</td>
                      <td style="border:none;" align="char" char=".">2.94 × 10<sup>–2</sup></td>
                      <td style="border:none;" align="char" char=".">1.69</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="t2fn1">
                    <label>a</label>
                    <p>All metabolites displayed were not
significantly altered in mild vs control or mild vs severe psoriasis
patients in either the exploratory or validation cohorts.</p>
                  </fn>
                  <fn id="t2fn2">
                    <label>b</label>
                    <p>Severe psoriasis patients vs healthy
controls.</p>
                  </fn>
                  <fn id="t2fn3">
                    <label>c</label>
                    <p>False discovery
rate (FDR) was directly
estimated according to the methods of Dabney and Storey.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup></p>
                  </fn>
                  <fn id="t2fn4">
                    <label>d</label>
                    <p>Fold
change between the two groups.</p>
                  </fn>
                  <fn id="t2fn5">
                    <label>e</label>
                    <p>KEGG Pathway map hsa00330: arginine
and proline metabolism.</p>
                  </fn>
                  <fn id="t2fn6">
                    <label>f</label>
                    <p>KEGG Pathway map hsa00260: glycine,
serine, and threonine metabolism.</p>
                  </fn>
                  <fn id="t2fn7">
                    <label>g</label>
                    <p>KEGG Pathway map hsa00250: alanine,
aspartate, and glutamate metabolism.</p>
                  </fn>
                  <fn id="t2fn8">
                    <label>h</label>
                    <p>KEGG Pathway map hsa00270: cysteine
and methionine metabolism.</p>
                  </fn>
                  <fn id="t2fn9">
                    <label>i</label>
                    <p>KEGG Pathway map hsa00430: taurine
and hypotaurine metabolism.</p>
                  </fn>
                  <fn id="t2fn10">
                    <label>j</label>
                    <p>KEGG Pathway map hsa00360: phenylalanine
metabolism.</p>
                  </fn>
                  <fn id="t2fn11">
                    <label>k</label>
                    <p>KEGG Pathway
map hsa00240: pyrimidine
metabolism.</p>
                  </fn>
                  <fn id="t2fn12">
                    <label>l</label>
                    <p>KEGG Pathway
map hsa00520: amino
sugar and nucleotide sugar metabolism.</p>
                  </fn>
                  <fn id="t2fn13">
                    <label>m</label>
                    <p>KEGG Pathway map hsa00600: sphingolipid
metabolism.</p>
                  </fn>
                  <fn id="t2fn14">
                    <label>o</label>
                    <p>Results obtained
from HILIC analysis.</p>
                  </fn>
                  <fn id="t2fn15">
                    <label>p</label>
                    <p>Results
obtained from reversed-phase
analysis.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The relationship
between psoriasis disease severity score (PASI)
and the metabolites identified in Table <xref rid="tbl2" ref-type="other">2</xref> was
further interrogated using correlation analysis and partial least-squares
(PLS) inner relation. Of the metabolites presented in Table <xref rid="tbl2" ref-type="other">2</xref>, 10 correlated with psoriasis disease severity
scores (<italic>r</italic> ≥ 0.5) in either the validation
or treated cohort (Table <xref rid="tbl3" ref-type="other">3</xref>). A PLS inner relation
was calculated between these 10 metabolites and PASI scores (Figure <xref rid="fig1" ref-type="fig">1</xref>), producing a significant multivariate association
(<italic>R</italic><sup>2</sup> = 0.80; <italic>p</italic> &lt; 0.0001)
between PASI scores (Figure <xref rid="fig1" ref-type="fig">1</xref>A) and metabolite
abundances (Figure <xref rid="fig1" ref-type="fig">1</xref>B). Threonine, citrulline,
and ornithine displayed the highest positive correlation with PASI
scores (Table <xref rid="tbl3" ref-type="other">3</xref>), whereas threonine, glutamine,
and ornithine were the most highly ranked multivariate predictors
of psoriasis severity (Figure <xref rid="fig1" ref-type="fig">1</xref>B). Following
Etanercept treatment, there was a significant reduction in PASI scores
associated with a normalization in all but two of the metabolites
that were altered in severe psoriasis patients within both cohorts
(Table <xref rid="tbl2" ref-type="other">2</xref>).</p>
              <fig id="fig1" position="float">
                <label>Figure 1</label>
                <caption>
                  <p>PLS inner relation between the 10 metabolites
identified to correlate
(<italic>r</italic> ≥ 0.5) with the psoriasis area and severity
index (PASI) in severe psoriasis patients pre- and post-treatment
with Etanercept (Table <xref rid="tbl3" ref-type="other">3</xref>). (A) The inner relation
for severe psoriasis and treated severe psoriasis patients from the
validation cohort (<italic>R</italic><sup>2</sup> = 0.80). For untreated
severe psoriasis only, <italic>R</italic><sup>2</sup> = 0.82; for
mild psoriasis only, <italic>R</italic><sup>2</sup> = 0.32; and for
mild, severe untreated, and treated psoriasis combined, <italic>R</italic><sup>2</sup> = 0.78. For the exploratory cohort, <italic>R</italic><sup>2</sup> = 0.91 for severe psoriasis, <italic>R</italic><sup>2</sup> = 0.49 for mild and severe psoriasis combined, and <italic>R</italic><sup>2</sup> = 0.26 for mild psoriasis only. (B) The variable
importance in projection (VIP) plot displaying the relative contributions
of the individual metabolites to the inner relation. S1P=sphingosine-1-phosphate.</p>
                </caption>
                <graphic xlink:href="pr-2014-00782g_0001" id="gr1" position="float"/>
              </fig>
              <table-wrap id="tbl3" position="float">
                <label>Table 3</label>
                <caption>
                  <title>Pearson’s
Correlations between
Disease Severity (PASI) and Plasma Metabolite Levels<xref rid="t3fn1" ref-type="table-fn">a</xref></title>
                </caption>
                <table frame="hsides" rules="groups" border="0">
                  <colgroup>
                    <col align="left"/>
                    <col align="char" char="."/>
                    <col align="char" char="."/>
                    <col align="char" char="."/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th style="border:none;" align="center">metabolite</th>
                      <th style="border:none;" align="center" char=".">exploratory
cohort<xref rid="t3fn2" ref-type="table-fn">b</xref></th>
                      <th style="border:none;" align="center" char=".">validation
cohort<xref rid="t3fn2" ref-type="table-fn">b</xref></th>
                      <th style="border:none;" align="center" char=".">treated cohort<xref rid="t3fn2" ref-type="table-fn">b</xref><sup>,</sup><xref rid="t3fn3" ref-type="table-fn">c</xref></th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td style="border:none;" align="left">arginine</td>
                      <td style="border:none;" align="char" char=".">0.52**</td>
                      <td style="border:none;" align="char" char=".">0.50***</td>
                      <td style="border:none;" align="char" char=".">0.60**</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">citrulline</td>
                      <td style="border:none;" align="char" char=".">0.73***</td>
                      <td style="border:none;" align="char" char=".">0.84***</td>
                      <td style="border:none;" align="char" char=".">0.70***</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">ornithine</td>
                      <td style="border:none;" align="char" char=".">0.43*</td>
                      <td style="border:none;" align="char" char=".">0.84***</td>
                      <td style="border:none;" align="char" char=".">0.75***</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">proline</td>
                      <td style="border:none;" align="char" char=".">0.77***</td>
                      <td style="border:none;" align="char" char=".">0.23</td>
                      <td style="border:none;" align="char" char=".">0.37*</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">hydroxyproline</td>
                      <td style="border:none;" align="char" char=".">0.20</td>
                      <td style="border:none;" align="char" char=".">0.43*</td>
                      <td style="border:none;" align="char" char=".">0.23</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">glycine</td>
                      <td style="border:none;" align="char" char=".">0.74***</td>
                      <td style="border:none;" align="char" char=".">0.47***</td>
                      <td style="border:none;" align="char" char=".">0.69***</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">serine</td>
                      <td style="border:none;" align="char" char=".">0.44**</td>
                      <td style="border:none;" align="char" char=".">0.73***</td>
                      <td style="border:none;" align="char" char=".">0.55**</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">threonine</td>
                      <td style="border:none;" align="char" char=".">0.84***</td>
                      <td style="border:none;" align="char" char=".">0.87***</td>
                      <td style="border:none;" align="char" char=".">0.88***</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">aspartate</td>
                      <td style="border:none;" align="char" char=".">0.05</td>
                      <td style="border:none;" align="char" char=".">0.26</td>
                      <td style="border:none;" align="char" char=".">0.17</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">glutamate</td>
                      <td style="border:none;" align="char" char=".">0.33</td>
                      <td style="border:none;" align="char" char=".">0.42*</td>
                      <td style="border:none;" align="char" char=".">0.09</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">glutamine</td>
                      <td style="border:none;" align="char" char=".">0.70***</td>
                      <td style="border:none;" align="char" char=".">0.66***</td>
                      <td style="border:none;" align="char" char=".">0.76***</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">cystine</td>
                      <td style="border:none;" align="char" char=".">0.79***</td>
                      <td style="border:none;" align="char" char=".">0.75***</td>
                      <td style="border:none;" align="char" char=".">0.56**</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">cystathionine</td>
                      <td style="border:none;" align="char" char=".">–0.27</td>
                      <td style="border:none;" align="char" char=".">–0.43</td>
                      <td style="border:none;" align="char" char=".">–0.19</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">methionine</td>
                      <td style="border:none;" align="char" char=".">0.39*</td>
                      <td style="border:none;" align="char" char=".">0.46**</td>
                      <td style="border:none;" align="char" char=".">0.74***</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">taurine</td>
                      <td style="border:none;" align="char" char=".">0.34</td>
                      <td style="border:none;" align="char" char=".">0.51**</td>
                      <td style="border:none;" align="char" char=".">0.22</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">phenylalanine</td>
                      <td style="border:none;" align="char" char=".">0.31</td>
                      <td style="border:none;" align="char" char=".">0.66**</td>
                      <td style="border:none;" align="char" char=".">0.37*</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">cytidine</td>
                      <td style="border:none;" align="char" char=".">0.63***</td>
                      <td style="border:none;" align="char" char=".">0.36*</td>
                      <td style="border:none;" align="char" char=".">0.34</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">acetylglucosamine</td>
                      <td style="border:none;" align="char" char=".">0.28</td>
                      <td style="border:none;" align="char" char=".">0.48**</td>
                      <td style="border:none;" align="char" char=".">0.45*</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">glucosylceramide
(C16:0)</td>
                      <td style="border:none;" align="char" char=".">0.50**</td>
                      <td style="border:none;" align="char" char=".">0.34</td>
                      <td style="border:none;" align="char" char=".">0.19</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">sphingosine-1-phosphate</td>
                      <td style="border:none;" align="char" char=".">0.35</td>
                      <td style="border:none;" align="char" char=".">0.50*</td>
                      <td style="border:none;" align="char" char=".">0.16</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="t3fn1">
                    <label>a</label>
                    <p>Metabolites in the validation and
treated cohorts with <italic>r</italic> ≥ 0.5 were used for
the regression with PASI score in Figure <xref rid="fig1" ref-type="fig">1</xref>.
Correlations include both mild and severe psoriasis patients for both
the exploratory and validation cohorts.</p>
                  </fn>
                  <fn id="t3fn2">
                    <label>b</label>
                    <p>The significance level is indicated
as follows: *, <italic>p</italic> &lt; 0.05; **, <italic>p</italic> &lt; 0.01; ***, <italic>p</italic> &lt; 0.001. The confounding effects
of age and BMI were tested via a linear regression model using STATA
11.</p>
                  </fn>
                  <fn id="t3fn3">
                    <label>c</label>
                    <p>Severe psoriasis patients
from the
validation cohort were treated with Etanercept for 12 weeks. Correlation
values are only for the treated patients.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Data sets were further interrogated using multivariate
methods.
PCA identified no outliers in the exploratory or validation cohorts
based on Hotelling’s T<sup>2</sup> (i.e., 95% confidence interval)
or DModX (data not shown). Multivariate classification modeling (OPLS-DA)
followed by feature selection was implemented to identify top metabolic
markers for disease-specific differences in plasma metabolite profiles
in both cohorts (Figure <xref rid="fig2" ref-type="fig">2</xref> and <xref rid="notes-2" ref-type="notes">Table S8</xref>). For the exploratory cohort, only severe psoriasis
produced significant models (<italic>p</italic> &lt; 0.05; mild vs
severe [<italic>Q</italic><sup>2</sup> = 0.605]; control vs severe
[<italic>Q</italic><sup>2</sup> = 0.741]). For the validation cohort,
all calculated models were significant (<italic>p</italic> &lt; 0.001)
and showed a disease severity-based increase in circulating metabolites
from control vs mild (<italic>Q</italic><sup>2</sup> = 0.626) to mild
vs severe (<italic>Q</italic><sup>2</sup> = 0.794) to control vs severe
(<italic>Q</italic><sup>2</sup> = 0.891). Etanercept treatment resulted
in metabolic profiles that were shifted from both severe untreated
(<italic>Q</italic><sup>2</sup> = 0.645) and controls (<italic>Q</italic><sup>2</sup> = 0.534), giving a unique pharmacological phenotype.
However, the Etanercept vs control OPLS-DA model was the weakest of
all generated models (<italic>p</italic> = 2.76 × 10<sup>–4</sup>), indicating that the treated cohort had a metabolic profile most
similar to the controls. All model statistics are provided in <xref rid="notes-2" ref-type="notes">Table S8</xref>.</p>
              <fig id="fig2" position="float">
                <label>Figure 2</label>
                <caption>
                  <p>OPLS-DA scores and variable importance
in projection (VIP) plots
from the curated models following 2 rounds of variable selection as
described in the <xref rid="sec2" ref-type="other">Experimental Section</xref>. (A)
Scores plot of control vs severe psoriasis in the exploratory cohort
(<italic>R</italic><sup>2</sup><italic>Y</italic> = 0.762 <italic>Q</italic><sup>2</sup> = 0.741, CV ANOVA <italic>p</italic> = 3.2
× 10<sup>–9</sup>, 1 + 0 components); (B) VIP plot of
control vs severe psoriasis in the exploratory cohort; (C) scores
plot of control vs severe psoriasis in the validation cohort (<italic>R</italic><sup>2</sup><italic>Y</italic> = 0.895 <italic>Q</italic><sup>2</sup> = 0.891, CV ANOVA <italic>p</italic> = 1.1 × 10<sup>–14</sup>, 1 + 0 components); (D) VIP plot of control vs severe
psoriasis in the validation cohort. S1P=sphingosine-1-phosphate.</p>
                </caption>
                <graphic xlink:href="pr-2014-00782g_0002" id="gr2" position="float"/>
              </fig>
              <p>Biochemical pathway enrichment
analysis of the psoriasis-associated
metabolic perturbations in common to both cohorts (Table <xref rid="tbl2" ref-type="other">2</xref>) was used to identify significant perturbations
(<italic>p</italic> ≤ 0.05) in 10 major biochemical pathways
(<xref rid="notes-2" ref-type="notes">Table S9</xref>). Partial correlation networks
were calculated to analyze empirical metabolite–metabolite
relationships in the context of the identified psoriasis-associated
metabolic perturbations (Figure <xref rid="fig3" ref-type="fig">3</xref>). On the
basis of the network topology, the three most psoriasis-impacted pathways
were those of alanine, aspartate, and glutamate metabolism (hsa00250);
glycine, serine, and threonine metabolism (hsa00260); and arginine
and proline metabolism (hsa00330). In particular, there was a dominant
psoriasis-dependent increase in the majority of urea cycle intermediates
including aspartate, arginine, ornithine, and citrulline. The confirmed
changes in metabolites (Table <xref rid="tbl2" ref-type="other">2</xref>) are highlighted
in these networks (thick borders) and can be classified into three
major correlated clusters (Figure <xref rid="fig3" ref-type="fig">3</xref>A): (1)
cytidine, cystathionine, acetylglucosamine, hydroxyproline, and taurine;
(2) ornithine, arginine, threonine, methionine, glutamine, glycine,
citrulline, and proline; and (3) phenylanine, cystine, GlcCer(C16:0),
aspartate, and glutamate. Metabolic changes within these three clusters,
with the exception of cystathionine, were positively correlated and
increased with psoriasis severity (Table <xref rid="tbl3" ref-type="other">3</xref>).
Etanercept treatment of severe psoriasis patients predominantly impacted
cluster 2 metabolites (Figure <xref rid="fig3" ref-type="fig">3</xref>B). Comparison
of the Etanercept treated group to healthy controls in the validation
cohort (Figure <xref rid="fig3" ref-type="fig">3</xref>C) revealed normalization in
the majority of the previously identified psoriasis-associated metabolic
perturbations with the exception of cystathionine and cystine.</p>
              <fig id="fig3" position="float">
                <label>Figure 3</label>
                <caption>
                  <p>Dependency
network displaying plasma metabolite relationships in
psoriasis in the context of the noted metabolic perturbations between
(A) severe untreated psoriasis and control, (B) severe treated and
severe untreated psoriasis, and (C) severe treated psoriasis and control
patients. Metabolites are connected based on partial correlation defined
relationships, and edge color and width display the direction and
magnitude of the FDR-adjusted Spearman rank order coefficient of correlation
(<italic>p</italic><sub>adj</sub> ≤ 0.05). Vertices represent
metabolites, with the shape and color displaying relative direction
and statistical significance (<italic>p</italic><sub>adj</sub> ≤
0.05) of the metabolic change for each respective comparison (i.e.,
panel A displays changes in severe psoriasis patients relative to
controls). Metabolites are sized according to each comparison’s
respective OPLS-DA model VIP (Figure <xref rid="fig2" ref-type="fig">2</xref>), and
species in common in the exploratory and validation models’
selected feature sets are highlighted with thick black borders.</p>
                </caption>
                <graphic xlink:href="pr-2014-00782g_0003" id="gr3" position="float"/>
              </fig>
            </sec>
            <sec sec-type="discussion" id="sec4">
              <title>Discussion</title>
              <p>There is an extensive
body of literature on psoriasis; however,
to date, there has been limited work investigating the underlying
metabolic processes associated with the disease.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> To the best of our knowledge, this is the first study utilizing
nontargeted metabolomics to study the effect of psoriasis severity
and the impact of Etanercept treatment on metabolism. Comparisons
of plasma metabolic profiles of psoriasis patients suggest that the
mild and severe disease states are not, from a metabolic perspective,
distinct pathologies but a progression of the disease along a shared
metabolic continuum. However, although distinct shifts in the circulatory
metabolic profiles of severe psoriasis patients were observed, it
is unclear as to the corresponding mechanism responsible.</p>
              <p>Psoriasis
severity was associated with an increase in three intermediates
of the urea cycle (citrulline, ornithine, and arginine). Shifts in
arginine and urea cycle metabolism have been previously reported in
psoriatic skin lesions,<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> and similar shifts
in urea cycle intermediates,<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> as well
as changes in glutamine and glutamate, have been associated with wound
healing.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> The commonality in markers for
psoriasis and wound healing is not surprising given that both psoriasis<sup><xref ref-type="bibr" rid="ref34">34</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> and wound healing<sup><xref ref-type="bibr" rid="ref36">36</xref>−<xref ref-type="bibr" rid="ref38">38</xref></sup> involve the production of new keratinocytes. The
urea cycle is an entry to the pathway for the synthesis of polayamines,
which are essential hormones in cell proliferation, a hallmark of
keratinocytosis in psoriasis.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> The polyamine
requirement may promote the mobilization of the urea cycle intermediate
arginine from its sites of synthesis to the skin, resulting in the
observed enhanced plasma levels.</p>
              <p>Protein synthesis demand in
the proliferating skin could also explain
the elevated amino acid profile in plasma. Psoriasis is associated
with changes in protein expression.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Cornification
of the epidermis requires different scaffolding proteins than that
in healthy cells, and a collection of support proteins such as small
proline-rich protiens (SPRP), hornirine (HNRN), and late cornified
envelope 3 A (LCE3A) were elevated up to 500 times in psoriasis skin
compared to that in healthy skin.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> The
production of these psoriasis-enriched proteins postulates an enhanced
influx of amino acids. The requirements of this process agree largely
with the observed increases in circulating amino acids. The most represented
amino acids in the regulated proteins in psoriasis were serine, proline,
glycine, and glutamine. This profile was not altered when a score
of fold change (psoriasis vs healthy) of protein expression was calculated
(<xref rid="notes-2" ref-type="notes">Table S10</xref>). To add to the requirement
burden, the major amino acids in human collagen 1 alpha are glycine
(27%) and proline (18%). While collagen is produced in the dermis,
which does not thicken in psoriasis, there are indications that collagen
turnover is higher in psoriasis patients, with reported enhanced activity
of collagen breakdown enzymes prolidase<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> and matrix metalloproteasease MMP1<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> (the
latter being 13 times higher in psoriasis patients compared to that
in healthy controls). Hydroxyproline, a marker for tissue collagen
degradation,<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> was upregulated in severe
psoriasis patients and normalized by Etanercept treatment. This agrees
with Garvican et al., who showed the ability of IL-1 or TNFα
to promote collagen degradation in ovine cartilage.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> The modest correlation of hydroxyproline with PASI score
may indicate different susceptibility of subjects, and further investigations
are necessary to examine if this susceptibility is reflected with
incidence of psoriatic arthritis.</p>
              <p>Another potential explanation
for the observed increase of circulating
amino acids would be due to cachexia or wasting syndrome, which is
the loss of lean body mass that can accompany systemic inflammatory
diseases.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> Cachexia has been linked with
psoriasis,<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> and cytokine inhibitors (e.g.,
anti-TNFα) have been suggested in the treatment of cachexia.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> TNFα in particular is thought to play
a role in both the anorexic effect via neuronal leptin receptors<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> as well as muscle wasting by enhancing protein
ubiquitation.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> A cachectic state of psoriasis
patients has been suggested due to a dual role of TNF, evidenced by
the increase in BMI during anti-TNFα treated patients.<sup><xref ref-type="bibr" rid="ref50">50</xref>,<xref ref-type="bibr" rid="ref51">51</xref></sup> Accordingly, it is possible that increased muscle protein breakdown,
a hallmark of cachexia, may explain the higher levels of circulating
amino acids observed in subjects with severe psoriasis. Muscle wasting
has been reported in other autoimmune diseases such as rheumatoid
arthritis;<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> however, this may not be associated
with changes in body weight.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> In our study,
BMI was marginally higher in severe psoriasis patients (Table <xref rid="tbl1" ref-type="other">1</xref>; <italic>p</italic> = 0.07), whereas the BMI values
of each subject did not change following treatment (<italic>p</italic> = 1.0). Treatment with anti-TNFα has previously been reported
to increase BMI,<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> but this was primarily
due to increases in fat-free mass, which was not examined in the current
cohort.</p>
              <p>Cachexia has not been widely studied from a metabolic
perspective,
and there is no consensus on plasma levels of metabolites in cachectic
patients or animal models. Peters et al. showed that in a tumor-bearing
mouse model plasma amino acids were upregulated.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> O’Connell et al. reported changes in lipids, glycerol,
and glucose, but not amino acids, in the plasma of a murine cancer
cachexia model.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> A follow up study observed
an increase in urea cycle amino acids and decreased glycine, alanine,
and serine in skeletal muscle.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> Ubhi et
al. observed a slightly significant (<italic>p</italic> = 0.05–0.1)
increase in plasma amino acids of cachectic compared to noncachectic
COPD patients.<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> Moreover, a number of
cachectic studies exhibited lower levels of circulating amino acids
during cachexia in clinical as well as animal studies.<sup><xref ref-type="bibr" rid="ref59">59</xref>−<xref ref-type="bibr" rid="ref61">61</xref></sup> However, a downregulation of circulating branched-chain amino acids,
which is thought to be a hallmark of cachexia,<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> was not observed in the current study. Accordingly, although
it is unlikely that the observed shifts in circulating amino acids
are due to cachexia, further evaluation is warranted.</p>
              <p>The dominant
effect of Etanercept treatment was observed in normalizing
the plasma levels of a large cluster of positively correlated metabolites
consisting of ornithine, arginine, proline, citrulline, glycine, glutamine,
threonine, and methionine (Figure <xref rid="fig3" ref-type="fig">3</xref>), specifically
within the arginine/proline and glycine, serine, and threonine pathways
(<xref rid="notes-2" ref-type="notes">Table S9</xref>). The biochemical mechanism leading
to the Etanercept-dependent reduction in these metabolites is unclear.
However, blocking the immune (autoimmune) response can lead to a reduced
signal for collagen and other keratinocyte-specific structural protein
production as well as keratinocytosis, resulting in a diminished requirement
for these metabolites. Etanercept acts by inhibiting the activity
of the cytokine TNFα,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> which is
involved in a wide range of biological activities. TNFα can
modulate the activity of nitric oxide synthase (NOS),<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> which is involved in the production of nitric oxide from
the conversion of arginine to citrulline.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> If Etanercept treatment, through inhibition of TNFα, was impacting
NOS activity, then shifts would be expected in the ratio of the citrulline-to-arginine
concentration following treatment. However, a large reduction in all
urea cycle metabolites, including arginine and citrulline, was observed,
which does not support the modulation of NOS activity as a mode of
action of treatment. Similarly, there are no reported mechanisms by
which Etanercept may lead to reductions in intermediates of glycine,
serine, and threonine metabolism. Etanercept could affect these metabolites
through modulation of NOS, for example, by modulating the flux of
aspartate between the urea cycle and threonine production. However,
an analysis of metabolite partial correlations (Figure <xref rid="fig3" ref-type="fig">3</xref>) reveals that aspartate levels are not directly linked to
urea cycle intermediates but instead to glutamate. Of the 20 metabolites
identified to shift with psoriasis, only cystathionine and cystine
were not normalized to healthy levels following Etanercept treatment
(Table <xref rid="tbl2" ref-type="other">2</xref> and Figure <xref rid="fig3" ref-type="fig">3</xref>). Cystathionine was not correlated with PASI scores prior to treatment
(Table <xref rid="tbl3" ref-type="other">3</xref>), which may explain the lack of response
and suggests a distinct mechanism. The fact that circulating amino
acid levels returned to normal following anti-TNFα treatment
in combination with the strong correlation to PASI score (before and
after treatment) indicates that amino acid metabolism is a good marker
for anti-TNFα responsiveness, as indicated by Kapoor et al.<sup><xref ref-type="bibr" rid="ref65">65</xref></sup></p>
              <p>Psoriasis patients are at increased risk
of metabolic syndrome
and diabetes,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> which share the common
element of insulin resistance. The excess amino acid availability
can stimulate the nutrient-sensitive mTOR/S6K pathway and inhibit
serine phosphorylation of insulin receptor substrate 1, which can
lead to an impairment in insulin-stimulated glucose disposal in skeletal
muscles and insulin-mediated inhibition of glucose production.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> Accordingly, although the chronic inflammatory
status of psoriasis certainly plays a direct role in the development
of insulin resistance, the observed enhanced circulating levels of
amino acids suggest the hypothesis that the mTOR/S6K pathway may contribute
to this risk. However, the validation of this tentative hypothesis
warrants further investigation.</p>
            </sec>
            <sec sec-type="conclusions" id="sec5">
              <title>Conclusions</title>
              <p>Although
the severity of psoriasis is clearly linked to levels
of circulating amino acids, the responsible mechanism(s) for the observed
shifts are unclear. The observed increased levels may be due to keratinocyte
hyperproliferation, increased proteolysis due to cachexia, or other
unknown pathways. During hyperproliferation, the increased demand
of protein building units, and specifically proline, may lead to a
strong shift in amino acid profiles. Alternatively, it can be hypothesized
that individuals with severe psoriasis are cachetic. There is a paucity
of information on cachexia in psoriasis, but the majority of studies
report an increase in BMI, which is not affected by Etanercept treatment
in this study. Accordingly, further investigations are required to
understand the significance of the observed amino acid shifts. It
is clear that Etanercept treatment significantly shifts the metabolic
profiles of psoriasis patients, reversing the distinct psoriasis metabotype
to that observed in healthy individuals, suggesting that focused metabolic
profiling can be used to monitor patient response to therapeutic intervention
systematically. The strong correlation of disease severity scoring
with the metabolite levels indicates that the observed metabolic shift
reflects a trajectory of disease progress rather than distinct disease
pathologies. It is also possible that circulating amino acid profiles
could be used as markers of both disease severity as well as responsiveness
to treatment.</p>
            </sec>
          </body>
          <back>
            <notes id="notes-2" notes-type="si">
              <title>Supporting Information Available</title>
              <p>Materials and Methods: Detailed
description of the methods used for analyzing the samples, data processing,
safety considerations, and metabolite annotation. Table S1: Analytical
internal standards used for HILIC and RP mode metabolomic analysis.
Table S2: List of the chemical reference standards used for annotating
metabolite features. Table S3: Summary of metabolic perturbations
associated with psoriasis disease severity for the exploratory cohort.
Table S4: Summary of metabolic perturbations associated with psoriasis
disease severity for the validation cohort. Table S5: Changes in putatively
identified (accurate mass) metabolite features in severe psoriasis
relative to controls in the exploratory cohort. Table S6: Changes
in putatively identified (accurate mass) metabolite features in severe
psoriasis relative to controls in the validation cohort. Table S7:
Changes in putatively identified (accurate mass) metabolite features
in severe psoriasis relative to controls in the treatment cohort.
Table S8: OPLS-DA model classification performance statistics for
the exploratory and validation cohorts. Table S9: Biochemical pathway
enrichment analysis of psoriasis-associated metabolic perturbations
in common to the exploratory and validation cohorts. Table S10: Requirement
of amino acids for the regulated proteins in psoriasis. This material
is available free of charge via the Internet at <uri xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>.</p>
            </notes>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="sifile1">
                <media xlink:href="pr500782g_si_001.pdf">
                  <caption>
                    <p>pr500782g_si_001.pdf</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
            <notes id="notes-1">
              <title>Author Contributions</title>
              <p><sup>⊥</sup> M.A.K. and S.G.S. contributed equally to this work.</p>
            </notes>
            <notes id="notes-4" notes-type="conflict-of-interest">
              <p>The authors
declare no competing financial interest.</p>
            </notes>
            <ack>
              <title>Acknowledgments</title>
              <p>We thank
research nurse Helena Griehsel for excellent technical
assistance. D.G. was supported by NIH Metabolomics Center grant no.
DK097154. M.S. acknowledges support from the Swedish Research Council
(K2012-57X-14202-11-6 and CERIC Linné Center), Stockholm County
Council (20120059), Hudfonden, and Psoriasisfonden. C.E.W. was supported
by the Center for Allergy Research (Cfa) and the Karolinska Institutet.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="ref1">
                <mixed-citation publication-type="journal" id="cit1"><name><surname>Rachakonda</surname><given-names>T. D.</given-names></name>; <name><surname>Schupp</surname><given-names>C. W.</given-names></name>; <name><surname>Armstrong</surname><given-names>A. W.</given-names></name><article-title>Psoriasis prevalence among adults
in the United States</article-title>. <source>J. Am. Acad. Dermatol.</source><year>2014</year>, <volume>70</volume>, <fpage>512</fpage>–<lpage>516</lpage>.<pub-id pub-id-type="pmid">24388724</pub-id></mixed-citation>
              </ref>
              <ref id="ref2">
                <mixed-citation publication-type="journal" id="cit2"><name><surname>Benoit</surname><given-names>S.</given-names></name>; et al. <article-title>Elevated serum levels
of calcium-binding S100 proteins A8 and A9
reflect disease activity and abnormal differentiation of keratinocytes
in psoriasis</article-title>. <source>Br. J. Dermatol.</source><year>2006</year>, <volume>155</volume>, <fpage>62</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">16792753</pub-id></mixed-citation>
              </ref>
              <ref id="ref3">
                <mixed-citation publication-type="journal" id="cit3"><name><surname>Henseler</surname><given-names>T.</given-names></name>; <name><surname>Christophers</surname><given-names>E.</given-names></name><article-title>Psoriasis
of early and late onset: characterization
of two types of psoriasis vulgaris</article-title>. <source>J. Am. Acad.
Dermatol.</source><year>1985</year>, <volume>13</volume>, <fpage>450</fpage>–<lpage>456</lpage>.<pub-id pub-id-type="pmid">4056119</pub-id></mixed-citation>
              </ref>
              <ref id="ref4">
                <mixed-citation publication-type="journal" id="cit4"><name><surname>McGonagle</surname><given-names>D.</given-names></name>; <name><surname>Lories</surname><given-names>R. J. U.</given-names></name>; <name><surname>Tan</surname><given-names>A. L.</given-names></name>; <name><surname>Benjamin</surname><given-names>M.</given-names></name><article-title>The concept of a “synovio-entheseal
complex” and its implications for understanding joint inflammation
and damage in psoriatic arthritis and beyond</article-title>. <source>Arthritis Rheum.</source><year>2007</year>, <volume>56</volume>, <fpage>2482</fpage>–<lpage>2491</lpage>.<pub-id pub-id-type="pmid">17665450</pub-id></mixed-citation>
              </ref>
              <ref id="ref5">
                <mixed-citation publication-type="journal" id="cit5"><name><surname>Mease</surname><given-names>P. J.</given-names></name>; et al. <article-title>Etanercept in the treatment of psoriatic arthritis and psoriasis:
a randomised trial</article-title>. <source>Lancet</source><year>2000</year>, <volume>356</volume>, <fpage>385</fpage>–<lpage>390</lpage>.<pub-id pub-id-type="pmid">10972371</pub-id></mixed-citation>
              </ref>
              <ref id="ref6">
                <mixed-citation publication-type="journal" id="cit6"><article-title>A genome-wide
association study identifies new psoriasis susceptibility loci and
an interaction between HLA-C and ERAP1</article-title>. <source>Nat.
Genet.</source><year>2010</year>, <volume>42</volume>, <fpage>985</fpage>–<lpage>990</lpage>.<pub-id pub-id-type="pmid">20953190</pub-id></mixed-citation>
              </ref>
              <ref id="ref7">
                <mixed-citation publication-type="journal" id="cit7"><name><surname>Enerbäck</surname><given-names>C.</given-names></name>; <name><surname>Martinsson</surname><given-names>T.</given-names></name>; <name><surname>Inerot</surname><given-names>A.</given-names></name>; <name><surname>Wahlström</surname><given-names>J.</given-names></name>; <name><surname>Enlund</surname><given-names>F.</given-names></name>; <name><surname>Yhr</surname><given-names>M.</given-names></name>; <name><surname>Swanbeck</surname><given-names>G.</given-names></name><article-title>Evidence that HLA-Cw6
determines early onset of psoriasis, obtained using sequence-specific
primers (PCR-SSP)</article-title>. <source>Acta Derm.-Venereol.</source><year>1997</year>, <volume>77</volume>, <fpage>4</fpage>.<pub-id pub-id-type="pmid">9059667</pub-id></mixed-citation>
              </ref>
              <ref id="ref8">
                <mixed-citation publication-type="journal" id="cit8"><name><surname>Nestle</surname><given-names>F. O.</given-names></name>; <name><surname>Kaplan</surname><given-names>D. H.</given-names></name>; <name><surname>Barker</surname><given-names>J.</given-names></name><article-title>Psoriasis</article-title>. <source>N. Engl. J. Med.</source><year>2009</year>, <volume>361</volume>, <fpage>496</fpage>–<lpage>509</lpage>.<pub-id pub-id-type="pmid">19641206</pub-id></mixed-citation>
              </ref>
              <ref id="ref9">
                <mixed-citation publication-type="journal" id="cit9"><name><surname>Carrascosa</surname><given-names>J. M.</given-names></name>; et al. <article-title>Obesity and psoriasis: inflammatory nature of obesity, relationship
between psoriasis and obesity, and therapeutic implications</article-title>. <source>Actas Dermo-Sifiliogr.</source><year>2014</year>, <volume>105</volume>, <fpage>31</fpage>–<lpage>44</lpage>.</mixed-citation>
              </ref>
              <ref id="ref10">
                <mixed-citation publication-type="journal" id="cit10"><name><surname>Azfar</surname><given-names>R. S.</given-names></name>; et al. <article-title>Icreased risk of diabetes mellitus and likelihood of receiving diabetes
mellitus treatment in patients with psoriasis</article-title>. <source>Arch. Dermatol.</source><year>2012</year>, <volume>148</volume>, <fpage>995</fpage>–<lpage>1000</lpage>.<pub-id pub-id-type="pmid">22710320</pub-id></mixed-citation>
              </ref>
              <ref id="ref11">
                <mixed-citation publication-type="journal" id="cit11"><name><surname>Ma</surname><given-names>C.</given-names></name>; <name><surname>Harskamp</surname><given-names>C. T.</given-names></name>; <name><surname>Armstrong</surname><given-names>E. J.</given-names></name>; <name><surname>Armstrong</surname><given-names>A. W.</given-names></name><article-title>The association
between psoriasis and dyslipidaemia: a systematic review</article-title>. <source>Br. J. Dermatol.</source><year>2013</year>, <volume>168</volume>, <fpage>486</fpage>–<lpage>495</lpage>.<pub-id pub-id-type="pmid">23106411</pub-id></mixed-citation>
              </ref>
              <ref id="ref12">
                <mixed-citation publication-type="journal" id="cit12"><name><surname>Azfar</surname><given-names>R. S.</given-names></name>; <name><surname>Gelfand</surname><given-names>J. M.</given-names></name><article-title>Psoriasis and metabolic disease: epidemiology and pathophysiology</article-title>. <source>Curr. Opin. Rheumatol.</source><year>2008</year>, <volume>20</volume>, <fpage>416</fpage>–<lpage>422</lpage>.<pub-id pub-id-type="pmid">18525354</pub-id></mixed-citation>
              </ref>
              <ref id="ref13">
                <mixed-citation publication-type="journal" id="cit13"><name><surname>Schön</surname><given-names>M. P.</given-names></name>; <name><surname>Boehncke</surname><given-names>W.-H.</given-names></name><article-title>Psoriasis</article-title>. <source>N. Engl. J. Med.</source><year>2005</year>, <volume>352</volume>, <fpage>1899</fpage>–<lpage>1912</lpage>.<pub-id pub-id-type="pmid">15872205</pub-id></mixed-citation>
              </ref>
              <ref id="ref14">
                <mixed-citation publication-type="journal" id="cit14"><name><surname>Iyer</surname><given-names>S.</given-names></name>; <name><surname>Yamauchi</surname><given-names>P.</given-names></name>; <name><surname>Lowe</surname><given-names>N. J.</given-names></name><article-title>Etanercept
for severe psoriasis and
psoriatic arthritis: observations on combination therapy</article-title>. <source>Br. J. Dermatol.</source><year>2002</year>, <volume>146</volume>, <fpage>118</fpage>–<lpage>121</lpage>.<pub-id pub-id-type="pmid">11841377</pub-id></mixed-citation>
              </ref>
              <ref id="ref15">
                <mixed-citation publication-type="journal" id="cit15"><name><surname>Sprott</surname><given-names>H.</given-names></name>; <name><surname>Glatzel</surname><given-names>M.</given-names></name>; <name><surname>Michel</surname><given-names>B. A.</given-names></name><article-title>Treatment of myositis with etanercept
(Enbrel®), a recombinant human soluble fusion protein of TNF-α
type II receptor and IgG1</article-title>. <source>Rheumatology</source><year>2004</year>, <volume>43</volume>, <fpage>524</fpage>–<lpage>526</lpage>.<pub-id pub-id-type="pmid">15024139</pub-id></mixed-citation>
              </ref>
              <ref id="ref16">
                <mixed-citation publication-type="journal" id="cit16"><name><surname>Lynch</surname><given-names>M.</given-names></name>; <name><surname>Kirby</surname><given-names>B.</given-names></name>; <name><surname>Warren</surname><given-names>R. B.</given-names></name><article-title>Treating
moderate to severe psoriasis—best
use of biologics</article-title>. <source>Expert Rev. Clin. Immunol.</source><year>2014</year>, <volume>10</volume>, <fpage>269</fpage>–<lpage>279</lpage>.<pub-id pub-id-type="pmid">24372444</pub-id></mixed-citation>
              </ref>
              <ref id="ref17">
                <mixed-citation publication-type="journal" id="cit17"><name><surname>Onesti</surname><given-names>J. K.</given-names></name>; <name><surname>Guttridge</surname><given-names>D. C.</given-names></name><article-title>Inflammation
based regulation of cancer cachexia</article-title>. <source>BioMed
Res. Int.</source><year>2014</year>, <volume>2014</volume>, <fpage>7</fpage>.</mixed-citation>
              </ref>
              <ref id="ref18">
                <mixed-citation publication-type="journal" id="cit18"><name><surname>Petersen</surname><given-names>A.-K.</given-names></name>; et al. <article-title>Epigenetics meets metabolomics:
an epigenome-wide association study
with blood serum metabolic traits</article-title>. <source>Hum. Mol.
Genet.</source><year>2014</year>, <volume>23</volume>, <fpage>534</fpage>–<lpage>545</lpage>.<pub-id pub-id-type="pmid">24014485</pub-id></mixed-citation>
              </ref>
              <ref id="ref19">
                <mixed-citation publication-type="journal" id="cit19"><name><surname>Suhre</surname><given-names>K.</given-names></name>; <name><surname>Gieger</surname><given-names>C.</given-names></name><article-title>Genetic variation in
metabolic phenotypes: study designs
and applications</article-title>. <source>Nat. Rev. Genet.</source><year>2012</year>, <volume>13</volume>, <fpage>759</fpage>–<lpage>769</lpage>.<pub-id pub-id-type="pmid">23032255</pub-id></mixed-citation>
              </ref>
              <ref id="ref20">
                <mixed-citation publication-type="journal" id="cit20"><name><surname>Fredriksson</surname><given-names>T.</given-names></name>; <name><surname>Pettersson</surname><given-names>U.</given-names></name><article-title>Severe psoriasis—oral
therapy with a new retinoid</article-title>. <source>Dermatologica</source><year>1978</year>, <volume>157</volume>, <fpage>238</fpage>–<lpage>244</lpage>.<pub-id pub-id-type="pmid">357213</pub-id></mixed-citation>
              </ref>
              <ref id="ref21">
                <mixed-citation publication-type="journal" id="cit21"><name><surname>Chambers</surname><given-names>M. C.</given-names></name>; et al. <article-title>A cross-platform toolkit
for mass spectrometry and proteomics</article-title>. <source>Nat. Biotechnol.</source><year>2012</year>, <volume>30</volume>, <fpage>918</fpage>–<lpage>920</lpage>.<pub-id pub-id-type="pmid">23051804</pub-id></mixed-citation>
              </ref>
              <ref id="ref22">
                <mixed-citation publication-type="journal" id="cit22"><name><surname>Smith</surname><given-names>C. A.</given-names></name>; <name><surname>Want</surname><given-names>E. J.</given-names></name>; <name><surname>O’Maille</surname><given-names>G.</given-names></name>; <name><surname>Abagyan</surname><given-names>R.</given-names></name>; <name><surname>Siuzdak</surname><given-names>G.</given-names></name><article-title>XCMS: processing
mass spectrometry data for metabolite profiling using nonlinear peak
alignment, matching, and identification</article-title>. <source>Anal.
Chem.</source><year>2006</year>, <volume>78</volume>, <fpage>779</fpage>–<lpage>787</lpage>.<pub-id pub-id-type="pmid">16448051</pub-id></mixed-citation>
              </ref>
              <ref id="ref23">
                <mixed-citation publication-type="computer-program" id="cit23"><person-group><collab>R Development Core Team</collab></person-group><source>R: A language
and environment for statistical computing</source>; <publisher-name>R Foundation for Statistical Computing</publisher-name>; <publisher-loc>Vienna, Austria</publisher-loc>, <year>2011</year>; <uri xlink:href="http://www.R-project.org/">http://www.R-project.org/</uri>. </mixed-citation>
              </ref>
              <ref id="ref24">
                <mixed-citation publication-type="journal" id="cit24"><name><surname>Benjamini</surname><given-names>Y.</given-names></name>; <name><surname>Hochberg</surname><given-names>Y.</given-names></name><article-title>Controlling the false
discovery rate—a practical
and powerful approach to multiple testing</article-title>. <source>J.
R. Stat. Soc. B</source><year>1995</year>, <volume>57</volume>, <fpage>289</fpage>–<lpage>300</lpage>.</mixed-citation>
              </ref>
              <ref id="ref25">
                <mixed-citation publication-type="computer-program" id="cit25"><person-group person-group-type="allauthors"><name><surname>Dabney</surname><given-names>A.</given-names></name>; <name><surname>Storey</surname><given-names>J. D.</given-names></name></person-group><source>qvalue:
Q-value estimation for false discovery rate control</source>, <year>2013</year>; <uri xlink:href="http://www.bioconductor.org/packages/release/bioc/html/qvalue.html">http://www.bioconductor.org/packages/release/bioc/html/qvalue.html</uri>.</mixed-citation>
              </ref>
              <ref id="ref26">
                <mixed-citation publication-type="journal" id="cit26"><name><surname>Wheelock</surname><given-names>A. M.</given-names></name>; <name><surname>Wheelock</surname><given-names>C. E.</given-names></name><article-title>Trials and tribulations
of ’omics data analysis:
assessing quality of SIMCA-based multivariate models using examples
from pulmonary medicine</article-title>. <source>Mol. BioSyst.</source><year>2013</year>, <volume>9</volume>, <fpage>2589</fpage>–<lpage>2596</lpage>.<pub-id pub-id-type="pmid">23999822</pub-id></mixed-citation>
              </ref>
              <ref id="ref27">
                <mixed-citation publication-type="journal" id="cit27"><name><surname>Xia</surname><given-names>J.</given-names></name>; <name><surname>Mandal</surname><given-names>R.</given-names></name>; <name><surname>Sinelnikov</surname><given-names>I. V.</given-names></name>; <name><surname>Broadhurst</surname><given-names>D.</given-names></name>; <name><surname>Wishart</surname><given-names>D. S.</given-names></name><article-title>MetaboAnalyst 2.0—a comprehensive
server for
metabolomic data analysis</article-title>. <source>Nucleic Acids Res.</source><year>2012</year>, <volume>40</volume>, <fpage>W127</fpage>–<lpage>W133</lpage>.<pub-id pub-id-type="pmid">22553367</pub-id></mixed-citation>
              </ref>
              <ref id="ref28">
                <mixed-citation publication-type="journal" id="cit28"><name><surname>Castelo</surname><given-names>R.</given-names></name>; <name><surname>Roverato</surname><given-names>A.</given-names></name><article-title>Reverse engineering
molecular regulatory networks from
microarray data with qp-graphs</article-title>. <source>J. Comput. Biol.</source><year>2009</year>, <volume>16</volume>, <fpage>213</fpage>–<lpage>227</lpage>.<pub-id pub-id-type="pmid">19178140</pub-id></mixed-citation>
              </ref>
              <ref id="ref29">
                <mixed-citation publication-type="journal" id="cit29"><name><surname>Shannon</surname><given-names>P.</given-names></name>; et al. <article-title>Cytoscape: a software
environment for integrated models of biomolecular
interaction networks</article-title>. <source>Genome Res.</source><year>2003</year>, <volume>13</volume>, <fpage>2498</fpage>–<lpage>2504</lpage>.<pub-id pub-id-type="pmid">14597658</pub-id></mixed-citation>
              </ref>
              <ref id="ref30">
                <mixed-citation publication-type="journal" id="cit30"><name><surname>Lu</surname><given-names>C.</given-names></name>; <name><surname>Deng</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>G.</given-names></name><article-title>Application
of metabolomics on diagnosis and treatment of patients with psoriasis
in traditional Chinese medicine</article-title>. <source>Biochim. Biophys.
Acta</source><year>2014</year>, <volume>1844</volume>, <fpage>280</fpage>–<lpage>288</lpage>.<pub-id pub-id-type="pmid">23747921</pub-id></mixed-citation>
              </ref>
              <ref id="ref31">
                <mixed-citation publication-type="journal" id="cit31"><name><surname>Abeyakirthi</surname><given-names>S.</given-names></name>; et al. <article-title>Arginase
is overactive in psoriatic skin</article-title>. <source>Br.
J. Dermatol.</source><year>2010</year>, <volume>163</volume>, <fpage>193</fpage>–<lpage>196</lpage>.<pub-id pub-id-type="pmid">20331451</pub-id></mixed-citation>
              </ref>
              <ref id="ref32">
                <mixed-citation publication-type="journal" id="cit32"><name><surname>Albina</surname><given-names>J.
E.</given-names></name>; <name><surname>Mills</surname><given-names>C. D.</given-names></name>; <name><surname>Henry</surname><given-names>W. L.</given-names></name>; <name><surname>Caldwell</surname><given-names>M. D.</given-names></name><article-title>Temporal expression
of different pathways of <sc>l</sc>-arginine metabolism in healing
wounds</article-title>. <source>J. Immunol.</source><year>1990</year>, <volume>144</volume>, <fpage>3877</fpage>–<lpage>3880</lpage>.<pub-id pub-id-type="pmid">2332635</pub-id></mixed-citation>
              </ref>
              <ref id="ref33">
                <mixed-citation publication-type="journal" id="cit33"><name><surname>Albina</surname><given-names>J. E.</given-names></name>; <name><surname>Abate</surname><given-names>J. A.</given-names></name>; <name><surname>Mastrofrancesco</surname><given-names>B.</given-names></name><article-title>Role of ornithine
as a proline precursor
in healing wounds</article-title>. <source>J. Surg. Res.</source><year>1993</year>, <volume>55</volume>, <fpage>97</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">8105150</pub-id></mixed-citation>
              </ref>
              <ref id="ref34">
                <mixed-citation publication-type="journal" id="cit34"><name><surname>Prinz</surname><given-names>J. C.</given-names></name>; et al. <article-title>T cell clones from psoriasis
skin lesions can promote keratinocyte
proliferation in vitro via secreted products</article-title>. <source>Eur. J. Immunol.</source><year>1994</year>, <volume>24</volume>, <fpage>593</fpage>–<lpage>598</lpage>.<pub-id pub-id-type="pmid">8125129</pub-id></mixed-citation>
              </ref>
              <ref id="ref35">
                <mixed-citation publication-type="journal" id="cit35"><name><surname>Schön</surname><given-names>M. P.</given-names></name>; <name><surname>Ruzicka</surname><given-names>T.</given-names></name><article-title>Psoriasis: the plot thickens</article-title>. <source>Nat. Immunol.</source><year>2001</year>, <volume>2</volume>, <fpage>91</fpage>.<pub-id pub-id-type="pmid">11175798</pub-id></mixed-citation>
              </ref>
              <ref id="ref36">
                <mixed-citation publication-type="journal" id="cit36"><name><surname>Martin</surname><given-names>P.</given-names></name><article-title>Wound healing—aiming
for perfect skin regeneration</article-title>. <source>Science</source><year>1997</year>, <volume>276</volume>, <fpage>75</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">9082989</pub-id></mixed-citation>
              </ref>
              <ref id="ref37">
                <mixed-citation publication-type="journal" id="cit37"><name><surname>Baker</surname><given-names>E. A.</given-names></name>; <name><surname>Leaper</surname><given-names>D. J.</given-names></name><article-title>Proteinases, their
inhibitors, and cytokine profiles
in acute wound fluid</article-title>. <source>Wound Repair Regener.</source><year>2000</year>, <volume>8</volume>, <fpage>392</fpage>–<lpage>398</lpage>.</mixed-citation>
              </ref>
              <ref id="ref38">
                <mixed-citation publication-type="journal" id="cit38"><name><surname>Mann</surname><given-names>A.</given-names></name>; <name><surname>Breuhahn</surname><given-names>K.</given-names></name>; <name><surname>Schirmacher</surname><given-names>P.</given-names></name>; <name><surname>Blessing</surname><given-names>M.</given-names></name><article-title>Keratinocyte-derived
granulocyte-macrophage colony stimulating factor accelerates wound
healing: stimulation of keratinocyte proliferation, granulation tissue
formation, and vascularization</article-title>. <source>J. Investig.
Dermatol.</source><year>2001</year>, <volume>117</volume>, <fpage>1382</fpage>–<lpage>1390</lpage>.<pub-id pub-id-type="pmid">11886498</pub-id></mixed-citation>
              </ref>
              <ref id="ref39">
                <mixed-citation publication-type="journal" id="cit39"><name><surname>Wei</surname><given-names>L. H.</given-names></name>; <name><surname>Wu</surname><given-names>G.</given-names></name>; <name><surname>Morris</surname><given-names>S. M.</given-names></name>; <name><surname>Ignarro</surname><given-names>L. J.</given-names></name><article-title>Elevated arginase I expression in
rat aortic smooth muscle cells increases cell proliferation</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2001</year>, <volume>98</volume>, <fpage>9260</fpage>–<lpage>9264</lpage>.<pub-id pub-id-type="pmid">11470919</pub-id></mixed-citation>
              </ref>
              <ref id="ref40">
                <mixed-citation publication-type="journal" id="cit40"><name><surname>de
Koning</surname><given-names>H. D.</given-names></name>; et al. <article-title>Expression profile of cornified envelope structural
proteins and keratinocyte differentiation-regulating proteins during
skin barrier repair</article-title>. <source>Br. J. Dermatol.</source><year>2012</year>, <volume>166</volume>, <fpage>1245</fpage>–<lpage>1254</lpage>.<pub-id pub-id-type="pmid">22329734</pub-id></mixed-citation>
              </ref>
              <ref id="ref41">
                <mixed-citation publication-type="journal" id="cit41"><name><surname>Guven</surname><given-names>B.</given-names></name>; <name><surname>Can</surname><given-names>M.</given-names></name>; <name><surname>Genc</surname><given-names>M.</given-names></name>; <name><surname>Koca</surname><given-names>R.</given-names></name><article-title>Serum prolidase activity in psoriasis
patients</article-title>. <source>Arch. Dermatol. Res.</source><year>2013</year>, <volume>305</volume>, <fpage>473</fpage>–<lpage>476</lpage>.<pub-id pub-id-type="pmid">23553128</pub-id></mixed-citation>
              </ref>
              <ref id="ref42">
                <mixed-citation publication-type="journal" id="cit42"><name><surname>Starodubtseva</surname><given-names>N. L.</given-names></name>; <name><surname>Sobolev</surname><given-names>V. V.</given-names></name>; <name><surname>Soboleva</surname><given-names>A. G.</given-names></name>; <name><surname>Nikolaev</surname><given-names>A. A.</given-names></name>; <name><surname>Bruskin</surname><given-names>S. A.</given-names></name><article-title>[Expression
of genes for metalloproteinases (MMP-1, MMP-2, MMP-9, and MMP-12)
associated with psoriasis]</article-title>. <source>Genetika</source><year>2011</year>, <volume>47</volume>, <fpage>1254</fpage>–<lpage>1261</lpage>.<pub-id pub-id-type="pmid">22117411</pub-id></mixed-citation>
              </ref>
              <ref id="ref43">
                <mixed-citation publication-type="journal" id="cit43"><name><surname>Kindt</surname><given-names>E.</given-names></name>; <name><surname>Gueneva-Boucheva</surname><given-names>K.</given-names></name>; <name><surname>Rekhter</surname><given-names>M. D.</given-names></name>; <name><surname>Humphries</surname><given-names>J.</given-names></name>; <name><surname>Hallak</surname><given-names>H.</given-names></name><article-title>Determination of hydroxyproline
in plasma and tissue
using electrospray mass spectrometry</article-title>. <source>J. Pharm.
Biomed. Anal.</source><year>2003</year>, <volume>33</volume>, <fpage>1081</fpage>–<lpage>1092</lpage>.<pub-id pub-id-type="pmid">14656599</pub-id></mixed-citation>
              </ref>
              <ref id="ref44">
                <mixed-citation publication-type="journal" id="cit44"><name><surname>Garvican</surname><given-names>E.
R.</given-names></name>; <name><surname>Vaughan-Thomas</surname><given-names>A.</given-names></name>; <name><surname>Redmond</surname><given-names>C.</given-names></name>; <name><surname>Gabriel</surname><given-names>N.</given-names></name>; <name><surname>Clegg</surname><given-names>P. D.</given-names></name><article-title>MMP-mediated
collagen breakdown induced by activated protein C in equine cartilage
is reduced by corticosteroids</article-title>. <source>J. Orthop. Res.</source><year>2010</year>, <volume>28</volume>, <fpage>370</fpage>–<lpage>378</lpage>.<pub-id pub-id-type="pmid">19777546</pub-id></mixed-citation>
              </ref>
              <ref id="ref45">
                <mixed-citation publication-type="journal" id="cit45"><name><surname>Schiaffino</surname><given-names>S.</given-names></name>; <name><surname>Dyar</surname><given-names>K. A.</given-names></name>; <name><surname>Ciciliot</surname><given-names>S.</given-names></name>; <name><surname>Blaauw</surname><given-names>B.</given-names></name>; <name><surname>Sandri</surname><given-names>M.</given-names></name><article-title>Mechanisms
regulating skeletal muscle growth and atrophy</article-title>. <source>FEBS J.</source><year>2013</year>, <volume>280</volume>, <fpage>4294</fpage>–<lpage>4314</lpage>.<pub-id pub-id-type="pmid">23517348</pub-id></mixed-citation>
              </ref>
              <ref id="ref46">
                <mixed-citation publication-type="journal" id="cit46"><name><surname>Yamanaka</surname><given-names>K.</given-names></name>; et al. <article-title>Persistent release of
IL-1s from skin is associated with systemic
cardio-vascular disease, emaciation and systemic amyloidosis: the
potential of anti-IL-1 therapy for systemic inflammatory diseases</article-title>. <source>PLoS One</source><year>2014</year>, <volume>9</volume>, <fpage>e104479</fpage>.<pub-id pub-id-type="pmid">25119884</pub-id></mixed-citation>
              </ref>
              <ref id="ref47">
                <mixed-citation publication-type="journal" id="cit47"><name><surname>Straub</surname><given-names>R.
H.</given-names></name>; <name><surname>Cutolo</surname><given-names>M.</given-names></name>; <name><surname>Buttgereit</surname><given-names>F.</given-names></name>; <name><surname>Pongratz</surname><given-names>G.</given-names></name><article-title>Energy regulation and
neuroendocrine–immune control in chronic inflammatory diseases</article-title>. <source>J. Int. Med.</source><year>2010</year>, <volume>267</volume>, <fpage>543</fpage>–<lpage>560</lpage>.</mixed-citation>
              </ref>
              <ref id="ref48">
                <mixed-citation publication-type="journal" id="cit48"><name><surname>Gan</surname><given-names>L.</given-names></name>; et al. <article-title>TNF-α
up-regulates protein level and cell surface expression
of the leptin receptor by stimulating its export via a PKC-dependent
mechanism</article-title>. <source>Endocrinology</source><year>2012</year>, <volume>153</volume>, <fpage>5821</fpage>–<lpage>5833</lpage>.<pub-id pub-id-type="pmid">23070544</pub-id></mixed-citation>
              </ref>
              <ref id="ref49">
                <mixed-citation publication-type="journal" id="cit49"><name><surname>LI</surname><given-names>Y.-P.</given-names></name>; et al. <article-title>TNF-α increases ubiquitin-conjugating activity
in skeletal
muscle by up-regulating UbcH2/E220k</article-title>. <source>FASEB J.</source><year>2003</year>, <volume>17</volume>, <fpage>1048</fpage>–<lpage>1057</lpage>.<pub-id pub-id-type="pmid">12773487</pub-id></mixed-citation>
              </ref>
              <ref id="ref50">
                <mixed-citation publication-type="journal" id="cit50"><name><surname>Florin</surname><given-names>V.</given-names></name>; <name><surname>Cottencin</surname><given-names>A. C.</given-names></name>; <name><surname>Delaporte</surname><given-names>E.</given-names></name>; <name><surname>Staumont-Sallé</surname><given-names>D.</given-names></name><article-title>Body weight
increment in patients treated with infliximab for plaque psoriasis</article-title>. <source>J. Eur. Acad. Dermatol. Venereol.</source><year>2013</year>, <volume>27</volume>, <fpage>e186</fpage>–<lpage>e190</lpage>.<pub-id pub-id-type="pmid">22621415</pub-id></mixed-citation>
              </ref>
              <ref id="ref51">
                <mixed-citation publication-type="journal" id="cit51"><name><surname>Saraceno</surname><given-names>R.</given-names></name>; et al. <article-title>Effect of anti-tumor necrosis factor-α
therapies on body mass
index in patients with psoriasis</article-title>. <source>Pharmacol.
Res.</source><year>2008</year>, <volume>57</volume>, <fpage>290</fpage>–<lpage>295</lpage>.<pub-id pub-id-type="pmid">18400510</pub-id></mixed-citation>
              </ref>
              <ref id="ref52">
                <mixed-citation publication-type="journal" id="cit52"><name><surname>Summers</surname><given-names>G.
D.</given-names></name>; <name><surname>Metsios</surname><given-names>G. S.</given-names></name>; <name><surname>Stavropoulos-Kalinoglou</surname><given-names>A.</given-names></name>; <name><surname>Kitas</surname><given-names>G. D.</given-names></name><article-title>Rheumatoid
cachexia and cardiovascular disease</article-title>. <source>Nat. Rev.
Rheumatol.</source><year>2010</year>, <volume>6</volume>, <fpage>445</fpage>–<lpage>451</lpage>.<pub-id pub-id-type="pmid">20647995</pub-id></mixed-citation>
              </ref>
              <ref id="ref53">
                <mixed-citation publication-type="journal" id="cit53"><name><surname>Llovera</surname><given-names>M.</given-names></name>; <name><surname>López-Soriano</surname><given-names>F. J.</given-names></name>; <name><surname>Argilés</surname><given-names>J. M.</given-names></name><article-title>Effects
of tumor necrosis factor-α on muscle-protein turnover in female
Wistar rats</article-title>. <source>J. Natl. Cancer Inst.</source><year>1993</year>, <volume>85</volume>, <fpage>1334</fpage>–<lpage>1339</lpage>.<pub-id pub-id-type="pmid">8340946</pub-id></mixed-citation>
              </ref>
              <ref id="ref54">
                <mixed-citation publication-type="journal" id="cit54"><name><surname>Renzo</surname><given-names>L. D.</given-names></name>; et al. <article-title>Prospective assessment
of body weight and body composition changes
in patients with psoriasis receiving anti-TNF-α treatment</article-title>. <source>Dermatol. Ther.</source><year>2011</year>, <volume>24</volume>, <fpage>446</fpage>–<lpage>451</lpage>.<pub-id pub-id-type="pmid">21910803</pub-id></mixed-citation>
              </ref>
              <ref id="ref55">
                <mixed-citation publication-type="journal" id="cit55"><name><surname>Peters</surname><given-names>S.</given-names></name>; <name><surname>van Helvoort</surname><given-names>A.</given-names></name>; <name><surname>Kegler</surname><given-names>D.</given-names></name>; <name><surname>Argilès</surname><given-names>J.</given-names></name>; <name><surname>Luiking</surname><given-names>Y.</given-names></name>; <name><surname>Laviano</surname><given-names>A.</given-names></name>; <name><surname>van Bergenhenegouwen</surname><given-names>J.</given-names></name>; <name><surname>Deutz</surname><given-names>N.</given-names></name>; <name><surname>Haagsman</surname><given-names>H.</given-names></name>; <name><surname>Gorselink</surname><given-names>M.</given-names></name>; <name><surname>van Norren</surname><given-names>K.</given-names></name><article-title>Dose-dependent effects of leucine supplementation on
preservation of muscle mass in cancer cachectic mice</article-title>. <source>Oncol. Rep.</source><year>2011</year>, <volume>26</volume>, <fpage>247</fpage>–<lpage>254</lpage>.<pub-id pub-id-type="pmid">21503587</pub-id></mixed-citation>
              </ref>
              <ref id="ref56">
                <mixed-citation publication-type="journal" id="cit56"><name><surname>O’Connell</surname><given-names>T.</given-names></name>; et al. <article-title>Metabolomic analysis of cancer cachexia reveals distinct lipid and
glucose alterations</article-title>. <source>Metabolomics</source><year>2008</year>, <volume>4</volume>, <fpage>216</fpage>–<lpage>225</lpage>.</mixed-citation>
              </ref>
              <ref id="ref57">
                <mixed-citation publication-type="journal" id="cit57"><name><surname>Der-Torossian</surname><given-names>H.</given-names></name>; et al. <article-title>Metabolic derangements
in the gastrocnemius and the effect of Compound
A therapy in a murine model of cancer cachexia</article-title>. <source>J. Cachexia Sarcopenia Muscle</source><year>2013</year>, <volume>4</volume>, <fpage>145</fpage>–<lpage>155</lpage>.<pub-id pub-id-type="pmid">23344889</pub-id></mixed-citation>
              </ref>
              <ref id="ref58">
                <mixed-citation publication-type="journal" id="cit58"><name><surname>Ubhi</surname><given-names>B. K.</given-names></name>; et al. <article-title>Targeted metabolomics identifies perturbations in amino acid metabolism
that sub-classify patients with COPD</article-title>. <source>Mol. BioSyst.</source><year>2012</year>, <volume>8</volume>, <fpage>3125</fpage>–<lpage>3133</lpage>.<pub-id pub-id-type="pmid">23051772</pub-id></mixed-citation>
              </ref>
              <ref id="ref59">
                <mixed-citation publication-type="journal" id="cit59"><name><surname>Pearlstone</surname><given-names>D. B.</given-names></name>; et al. <article-title>Effect of enteral and
parenteral nutrition on amino acid levels in
cancer patients</article-title>. <source>JPEN, J. Parenter. Enteral
Nutr.</source><year>1995</year>, <volume>19</volume>, <fpage>204</fpage>–<lpage>208</lpage>.<pub-id pub-id-type="pmid">8551648</pub-id></mixed-citation>
              </ref>
              <ref id="ref60">
                <mixed-citation publication-type="journal" id="cit60"><name><surname>Blumberg</surname><given-names>D.</given-names></name>; <name><surname>Hochwald</surname><given-names>S.</given-names></name>; <name><surname>Burt</surname><given-names>M.</given-names></name>; <name><surname>Donner</surname><given-names>D.</given-names></name>; <name><surname>Brennan</surname><given-names>M. F.</given-names></name><article-title>Tumor necrosis
factor alpha stimulates gluconeogenesis from alanine in vivo</article-title>. <source>J. Surg. Oncol.</source><year>1995</year>, <volume>59</volume>, <fpage>220</fpage>–<lpage>225</lpage>.<pub-id pub-id-type="pmid">7630167</pub-id></mixed-citation>
              </ref>
              <ref id="ref61">
                <mixed-citation publication-type="journal" id="cit61"><name><surname>Preston</surname><given-names>T.</given-names></name>; et al. <article-title>Fibrinogen synthesis is elevated in fasting cancer patients with
an acute phase response</article-title>. <source>J. Nutr.</source><year>1998</year>, <volume>128</volume>, <fpage>1355</fpage>–<lpage>1360</lpage>.<pub-id pub-id-type="pmid">9687556</pub-id></mixed-citation>
              </ref>
              <ref id="ref62">
                <mixed-citation publication-type="journal" id="cit62"><name><surname>Ubhi</surname><given-names>B. K.</given-names></name>; et al. <article-title>Metabolic profiling
detects biomarkers of protein degradation in
COPD patients</article-title>. <source>Eur. Respir. J.</source><year>2012</year>, <volume>40</volume>, <fpage>345</fpage>–<lpage>355</lpage>.<pub-id pub-id-type="pmid">22183483</pub-id></mixed-citation>
              </ref>
              <ref id="ref63">
                <mixed-citation publication-type="journal" id="cit63"><name><surname>Gazzinelli</surname><given-names>R. T.</given-names></name>; <name><surname>Eltoum</surname><given-names>I.</given-names></name>; <name><surname>Wynn</surname><given-names>T. A.</given-names></name>; <name><surname>Sher</surname><given-names>A.</given-names></name><article-title>Acute cerebral toxoplasmosis
is induced by in vivo neutralization of TNF-alpha and correlates with
the down-regulated expression of inducible nitric oxide synthase and
other markers of macrophage activation</article-title>. <source>J. Immunol.</source><year>1993</year>, <volume>151</volume>, <fpage>3672</fpage>–<lpage>3681</lpage>.<pub-id pub-id-type="pmid">7690809</pub-id></mixed-citation>
              </ref>
              <ref id="ref64">
                <mixed-citation publication-type="journal" id="cit64"><name><surname>Castillo</surname><given-names>L.</given-names></name>; et al. <article-title>Plasma arginine and
citrulline kinetics in adults given adequate
and arginine-free diets</article-title>. <source>Proc. Natl. Acad. Sci.
U.S.A.</source><year>1993</year>, <volume>90</volume>, <fpage>7749</fpage>–<lpage>7753</lpage>.<pub-id pub-id-type="pmid">8356080</pub-id></mixed-citation>
              </ref>
              <ref id="ref65">
                <mixed-citation publication-type="journal" id="cit65"><name><surname>Kapoor</surname><given-names>S.
R.</given-names></name>; et al. <article-title>Metabolic
profiling predicts response to anti-tumor necrosis factor
α therapy in patients with rheumatoid arthritis</article-title>. <source>Arthritis Rheum.</source><year>2013</year>, <volume>65</volume>, <fpage>1448</fpage>–<lpage>1456</lpage>.<pub-id pub-id-type="pmid">23460124</pub-id></mixed-citation>
              </ref>
              <ref id="ref66">
                <mixed-citation publication-type="journal" id="cit66"><name><surname>Tremblay</surname><given-names>F.</given-names></name>; et al. <article-title>Overactivation of S6 kinase 1 as a cause of human insulin resistance
during increased amino acid availability</article-title>. <source>Diabetes</source><year>2005</year>, <volume>54</volume>, <fpage>2674</fpage>–<lpage>2684</lpage>.<pub-id pub-id-type="pmid">16123357</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
